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ABSTRACT 
 
JOE BRAUN: Relationship between Serum and Meconium Biomarkers of Prenatal Tobacco 
Smoke Exposure and their Association with Infant and Child Growth (Under the direction of Julie 
Daniels) 
 
 
Prenatal active and secondhand tobacco smoke exposures remain a prevalent and 
preventable risk factor for adverse infant and childhood health outcomes.  I used a prospective 
birth cohort of 389 mothers and their infants who were followed from early pregnancy to three 
years of age to address two specific aims.  First, I validated the utility of meconium as a 
biological matrix to quantify prenatal tobacco smoke exposure.  Second, I examined the 
association between prenatal tobacco smoke exposure and early childhood body mass index 
(BMI).    
 I validated the utility of meconium tobacco smoke metabolites as biomarkers of prenatal 
tobacco smoke exposure against self-report and serum cotinine biomarkers of tobacco smoke 
exposure.  I also estimated and compared associations between meconium and serum 
metabolite concentrations and infant birth weight.  Nicotine, cotinine, and trans-3’-
hydroxycotinine were detected in the majority of meconium samples (57-80%).  Meconium 
tobacco smoke metabolite concentrations were positively associated with self-report and serum 
cotinine biomarkers of tobacco smoke exposure.  The association between meconium 
metabolite concentrations and infant birth weight was similar to serum cotinine associations.  
Meconium is a promising biological matrix to quantify prenatal environmental toxicant exposure; 
however, meconium tobacco smoke metabolite concentrations did not provide additional 
information that could be obtained from a single serum cotinine measurement. 
 ii
 In the second aim, prenatal tobacco smoke exposures were quantified using maternal 
self-report and serum cotinine biomarkers.  BMI was calculated from weight and height 
measurements taken at birth, 4 weeks, and 1, 2, and 3 years of age.  During pregnancy, 51% of 
women had cotinine levels consistent with SHS exposure and 10% had cotinine concentrations 
indicative of active smoking.  After adjustment for confounders, both self-report and serum 
biomarkers of active tobacco smoke exposures were associated with elevated BMI at 2 and 3 
years of age.  Estimates of association between self-reported SHS exposures and BMI were 
attenuated towards the null relative to serum cotinine concentration associations.  These results 
suggest that prenatal tobacco smoke exposures may play a role in the development of 
overweight in early childhood and that self-reported prenatal SHS exposures are non-
differentially misclassified, resulting in biased estimates of association with childhood BMI. 
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CHAPTER 1: INTRODUCTION AND SPECIFIC AIMS 
 
 Prenatal tobacco smoke exposure is a prevalent and preventable risk factor for low birth 
weight (LBW), preterm birth, spontaneous abortion, infant mortality, and behavioral problems in 
childhood.1-6   Despite declines in the prevalence of smoking and exposure to second hand 
smoke (SHS) in the United States (US), 10% to 11% of mothers report smoking during 
pregnancy and a high proportion of women have exposure to tobacco smoke at home or work.7-
9  Even though the dangers of smoking are well known,10, 11 prenatal tobacco smoke exposure is 
a growing problem in the developing world. 12-14   
Both active and second hand tobacco smoke exposure have been consistently 
associated with restricted fetal growth.10, 11  Women who smoke during pregnancy give birth to 
infants who on average weigh 350 grams less than infants of non-smoking women,15 while 
women exposed to SHS give birth to infants weighing 40-80 grams less than unexposed 
women.6, 16, 17 
Reductions in birth weight related to prenatal tobacco smoke exposure may have lasting 
consequences on growth and development across the lifespan.  A growing body of literature 
indicates that active prenatal tobacco smoke exposure increases the risk for overweight and 
obesity in childhood by approximately 50%.18-20  Children born to active smokers are shorter and 
lighter at birth and go through a period of catch-up growth marked by increases in weight which 
results in increased body mass index (BMI).19  Less is known about the association between 
prenatal SHS exposure and childhood BMI and growth.21, 22  Prenatal SHS exposure may also 
increase the risk of overweight and obesity because of its association with low birth weight and 
decreased birth length.5, 6, 11   
Sensitive and accurate biomarkers of prenatal tobacco smoke exposure are needed to 
study secondhand tobacco smoke exposures.  Self-report of tobacco smoke is insensitive to 
many potential sources of tobacco exposure since many women are unaware of their 
presence.9, 23  Meconium is a potentially promising biological matrix that is thought to represent 
cumulative exposure to environmental toxicants in the latter two-thirds of pregnancy.24  Some 
investigators have used meconium as a biological matrix for examining prenatal tobacco smoke 
exposure.25-29  To date, no studies have compared meconium metabolite concentrations to 
serial self-reported or biomarkers of prenatal tobacco smoke exposure.  Prior studies have not 
elucidated if meconium tobacco smoke metabolites are indicative of cumulative gestational 
exposure to tobacco smoke.25, 27, 29  In addition only two studies have examined the association 
between meconium tobacco smoke metabolite concentrations and infant health outcomes, but 
did not compare these associations to self-report or serum markers of exposure.26, 28   The 
association between meconium metabolite concentrations and infant or child health outcomes 
needs to be compared to the associations with other validated biomarkers.  The predictable 
association between prenatal tobacco smoke exposure and birth weight provides an ideal 
“model system” to compare meconium to other validated biomarkers of tobacco smoke 
exposure, as well as a measure of internal validity of the presented study.   
I will use data from a prospective cohort of 389 women and their children to complete 
two aims.   
Aim 1: Examine the utility of meconium nicotine, cotinine, and OH-cotinine as a biomarker of 
prenatal tobacco smoke exposure. 
Sub Aim 1.1: Determine if three serial serum cotinine concentrations and self-reported 
tobacco smoke exposures are positively associated with meconium tobacco smoke 
metabolites.   
Sub Aim 1.2: Determine if meconium tobacco smoke metabolites represent cumulative 
exposure to gestational tobacco smoke.     
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Sub Aim 1.3: Compare the associations between serum and meconium biomarkers of 
prenatal tobacco smoke exposure and infant birth weight.   
Aim 2: Estimate the association between prenatal secondhand and active tobacco smoke 
exposure and childhood BMI in the first three years of life. 
Sub Aim 2.1: Compare the association between self-report and serum biomarkers of 
prenatal tobacco smoke exposure and BMI over the first three years of life. 
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CHAPTER 2: LITERATURE REVIEW 
 
A. Biomarkers of Tobacco Smoke 
A.1. Measuring Exposure to Tobacco Smoke 
 Tobacco smoke is composed of over 4,000 compounds including nicotine, lead, 
cadmium, polycyclic aromatic hydrocarbons, and carbon monoxide.30  Pregnant women can be 
exposed to tobacco smoke either through active or passive smoking.  Active smokers are 
primarily exposed to inhaled mainstream (MS) smoke and to a lesser extent, sidestream (SS) 
smoke.  SS smoke is the partially combusted material that is burnt off between inhalations.  
Secondhand smokers are exposed to both exhaled MS smoke and SS smoke.  Both MS and 
SS smoke contain the same chemical constituents but in different concentrations due to the 
incomplete combustion of SS smoke.31  MS smoke contains lower concentrations of 
carcinogenic and toxic substances than SS smoke due to a higher burning temperature and 
more complete combustion of the chemical constituents of the cigarette.  Most studies of 
tobacco smoke exposure treat MS and SS smoke as the same exposures; however, it is 
important to recognize that the different concentrations of MS and SS smoke inhaled by active 
and secondhand smokers produces a continuum of exposure.  Depending on the health 
outcome under study, there may be very distinct or overlapping effects of both secondhand and 
active exposure due to the different chemical composition of MS and SS smoke.   
 Measuring exposure to any environmental toxin is difficult.  The difficulty is compounded 
by whether investigators measure exposure or effective dose.  While both are of interest, they 
have the potential to produce different results.  Historically, active smoking has been measured 
using questionnaires, the results of which are used as proxies for inhaled dose.  Among active 
smokers, the quantity, brand, and depth of inhalation are often assessed to determine inhaled 
dose.  In addition, investigators often ask pregnant women the amount smoked during each 
trimester of pregnancy and whether she quit smoking during pregnancy.  SHS exposure has 
typically been measured through self-report.  Initial studies of the health effects of SHS 
exposure used spousal smoking as a proxy for SHS exposure.32  More sophisticated 
questionnaires were developed that ask about the number of smokers, the quantity of cigarettes 
smoked by other smokers, the time spent in a smoky environment, and the smokiness of the 
environment.  
 Questionnaire based methods result in under-reporting and misclassification of active 
smoking among pregnant women due to social stigma and socioeconomic (SES) factors.23, 33-35  
In addition, women tend to underreport active smoking when questioned antenatally compared 
to their perinatal reports.36, 37  Single measurements of active smoking status may lead to further 
misclassification if women quit smoking early in pregnancy, but resume later, or vice versa.  
Single measurements of active smoking may also miss critical periods of fetal susceptibility. 
  Questionnaires also cause substantial misclassification of SHS exposure among non-
smokers for several reasons.  First, different exposure metrics (hours, number of smokers, or 
smokiness) have been used in various studies, which reduces the comparability between 
studies.5  Second, most studies dichotomize SHS exposure as exposed vs. non-exposed.  
While grouping all women with any exposure to SHS can increase power, it leads to increased 
exposure misclassification within the two groups.  This method would classify a person exposed 
to one smoker four-feet away for eight hours a day the same as another person exposed to 
three smokers 100 feet away for 4 hours a day.  Third, women (and men) are likely to 
underestimate their true exposure to SHS.  It has been demonstrated that women who report no 
exposure to SHS at home or work have measurable levels of cotinine (a biomarker of nicotine 
exposure).38, 39  Finally, questionnaire based methods measure the exposure of an individual, 
not their received dose.  When studying infant outcomes, it can be preferable to have a 
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measure of the internal dose that a woman receives.  Variations in ventilation, breathing rate, 
and genetics could cause variability in the received dose at the same levels of exposure.31, 40 
A.2. Cotinine as a Biomarker of Tobacco Smoke Exposure 
 
 The National Research Council proposed the following criteria for biomarkers of tobacco 
smoke exposure: 1) should be unique or nearly unique for tobacco, 2) should be easily 
detectable, 3) should be detected with exposure to a variety of tobacco products or sources, 
and 4) should have a concentration proportional to other tobacco smoke constituents.30  Based 
on these criteria, serum cotinine concentrations are considered the best biomarker of active and 
secondhand tobacco smoke exposure.30, 31, 41  It is easily detectable in urine, saliva, serum, hair, 
and stool.  Advances in analytical chemistry techniques have allowed cotinine to be detected in 
serum at levels two orders of magnitude lower (2 ng/mL vs. 0.015 ng/mL) than methods used 20 
years ago.42  Serum, saliva, urinary, and hair cotinine levels can accurately discriminate 
between smokers and non-smokers.  There is little evidence to suggest that exogenous nicotine 
from fruits and vegetables (tomatoes, cauliflower, or eggplant) could result in a substantial 
increase in serum cotinine levels.30  For example, a person would have to consume 130 grams 
of eggplant or 250 grams of pureed tomatoes to raise their serum cotinine levels by 1 ng/mL.   
 Numerous studies have documented elevated serum cotinine levels among women who 
report no active or secondhand tobacco smoke exposures.9, 23, 43-45  The degree of 
misclassification of smoking based on self-report seems to vary considerably.  It is likely 
influenced by cultural norms, social stigma, and SES status.  Given the potential for 
misclassification, a biomarker of tobacco smoke exposure during pregnancy is preferable.  .   
A.3. Meconium Cotinine as a Marker of Tobacco Smoke Exposure 
 
The use of serum cotinine levels as a biomarker of tobacco smoke exposure in pregnant 
women has several related shortcomings.  First, women are often unaware of their pregnancy 
early in gestation.  After women do become aware of their pregnancy, they often change their 
smoking habits as a result of pressure from friends and family, clinicians, and society.34, 35  
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Second, women may be intermittently exposed to secondhand tobacco smoke, resulting in 
exposure misspecification depending on the timing of exposure and serum measurement.  
Cumulative biomarkers of tobacco smoke exposure may be a potential solution to these two 
problems and would allow an investigator to determine whether the sum of exposure over 
gestation is an important predictor of health outcomes. 
One novel biomarker of cumulative gestational exposure to environmental toxicants is 
meconium.  Meconium is the first stools passed by an infant after birth.  The majority of 
meconium remains in the intestine of the newborn at the time of birth, but occasionally fetal 
stress will cause the newborn to expel meconium in utero.  Meconium is formed from swallowed 
amniotic fluid, shed epithelial cells, and intestinal secretions beginning in the 13th week of 
gestation.24  Thus, meconium concentrations of environmental toxins reflect exposure in the 
latter two-thirds of pregnancy and may provide a better estimate of cumulative exposure than 
single or serial serum or urine cotinine measurements.   
Several studies suggest that meconium is metabolically inert, making it an ideal matrix 
for analyzing chemicals with relatively short half-lives (nicotine, pesticides, cocaine, alcohol, and 
barbiturates).46  This is substantiated by results showing that meconium has a greater sensitivity 
for illicit drugs compared to maternal urine, fetal urine, and cord blood samples.47  Several 
studies have detected tobacco smoke metabolites in meconium and found that they are 
positively correlated with self-report or biomarkers of prenatal tobacco smoke exposure.25, 27-29, 48  
However, these studies have not had serial measurements of biomarkers or self-reports of 
prenatal tobacco smoke exposure throughout pregnancy to confirm that meconium metabolites 
represent cumulative gestational exposure.  In addition, many of these studies have been 
conducted on relatively small samples of women (<50) and some have used outdated analytical 
chemistry techniques.   
To date, only two studies have examined the association between meconium cotinine 
levels and infant or child health outcomes.  Gray et al. found decrements in birth weight, length, 
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and head circumference in a sample of 51 women with detectable meconium metabolite 
tobacco smoke concentrations.  They also detected similar decrements associated with self-
reported prenatal tobacco smoke exposure, but assumed that detectable meconium metabolite 
concentrations were indicative of active smoking.  Infants with detectable meconium metabolite 
concentrations could have been exposed to secondhand or active tobacco smoke exposure.   
The second study conducted by Nuesslein et al. reported a 4.9-fold (95% CI: 1.2, 20.3) 
odds of lower respiratory tract infections in the first year of life among infants with greater than 
median meconium concentrations compared to infants with meconium concentrations below the 
median.26  However, they were unable to validate their intriguing results against other markers 
of prenatal tobacco smoke exposure.    
While meconium is reflective of total gestational exposure to environmental toxicants, it 
does not allow the identification of the timing of exposure.  This may be detrimental when 
attempting to define critical windows of susceptibility.  However, this pitfall may be offset by the 
difficulty in obtaining multiple serum cotinine measurements during pregnancy.  In addition, 
transient exposures to environmental toxins have the potential to be associated with delays in 
growth and development which may not be captured even when collecting multiple serum 
measurements.   
B. Fetal and Childhood Growth     
B.1. Measurement of Birth Weight and Fetal Growth Restriction 
 LBW and decreased birth weight are used as indicators of fetal growth restriction 
because they are accurately measured and readily available on birth certificates and medical 
records.49, 50  Among term infants, decreases in birth weight can provide an accurate indicator of 
fetal growth restriction.51 
B.2. Etiology of Low Birth Weight 
 
 Low birth weight affects 7.5% of live-born infants in the US.52  Infants are born low birth 
weight as a result of intrauterine growth restriction  or premature birth.  Preterm birth is one of 
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many predictors of low birth weight.  Many of the same risk factors for preterm birth are 
associated with low birth weight.  For instance, a nutritional factor that reduces fetal growth may 
also decrease gestational age.  Disentangling the effects of an environmental factor on 
gestational age and low birth weight is difficult and requires many strong assumptions or 
advanced modeling techniques.53-55  
Risk factors and predictors of low birth weight fall into maternal and fetal factors.  
Maternal factors include malnutrition, alcohol and cocaine use, certain medications, 
hypertension, autoimmune disorders, and lifestyle factors including active and secondhand 
smoking.  Fetal factors include multiple gestation, infection, aneuploidy, and congenital 
malformations.  Certain fetal disorders such as vascular, anatomical, and chromosomal 
abnormalities can also result in low birth weight.  Some data suggest that air pollution may also 
be responsible for small declines in birth weight.56, 57  
 The use of birth weight as an indicator for fetal growth is not without critics.51, 58  
Differences in the estimated gestational age of infants may be responsible for reported 
decreases in birth weight, thus some infants who are less than 2500 grams may be 
misclassified as low birth weight, even though the infant is at a normal weight for their given 
gestational age.  In order to correct for differences in fetal growth over time, some researchers 
use standardized measures of infant size based on their gestational age at birth.  
B.3. Complications Related Low Birth Weight 
 
 LBW infants are at increased risk for death in the first year of life.59, 60  Morbidity and 
mortality from respiratory problems and infection are also associated with LBW.61-63  Treatment 
of complications related to LBW has substantial financial costs to society.64  In 2001, admissions 
for LBW totaled $5.8 billion, representing almost half of the all the costs of infant 
hospitalizations.  Beyond the quantitative costs, parents of LBW infants suffer unimaginable 
hardships. 
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 The effects of LBW are not limited to the first year of life.  Decreases in birth weight are 
associated with wheeze, cough, and respiratory infection in childhood among term infants.65  
Infants born LBW also have abnormal neurodevelopment in early childhood compared to their 
normal birth weight peers in.66, 67  These deficits persist into later childhood where LBW children 
have decreased cognitive aptitude and academic skills.68, 69  In addition, children born LBW are 
at increased risk for externalizing behaviors including attention-deficit/hyperactivity disorder  and 
conduct disorder.68, 70, 71   While there is some evidence that medical interventions may improve 
neurodevelopmental outcomes for children born LBW, it is imperative to prevent these 
outcomes given their substantial financial and societal cost.72 
B.4. Birth Weight and Risk of Adult Mortality and Disease  
 Epidemiological studies that birth weight may play an important role in the development 
of circulatory disease or metabolic disorders in adulthood.  In 1989, Barker observed that low 
weight in infancy was associated with mortality from ischemic heart disease.73  Additional 
studies have confirmed that reduced birth weight is associated with diabetes and heart 
disease.74-76  Baker et al. reported a 17% increased hazard (95% CI: 1.11, 1.22) for all-cause 
mortality among a cohort of Danish men and women who were between 2,000 and 2,750 grams 
at birth compared to those with a birth weight between 3,251 and 3,750 grams.77   
 The Barker Hypothesis posits that environmental factors act in early life to program the 
risk for the onset of adult metabolic and cardiovascular disease.78, 79  Exposure to factors that 
decrease birth weight and alter postnatal growth trajectory may increase the risk for adult 
disease morbidity and mortality.77, 80, 81    Prenatal growth restriction and alterations in early life 
growth trajectories may result in an overshoot of genetically programmed size and metabolism.  
Thus, factors like tobacco smoke that impair or restrict growth in early life may increase the risk 
for later morbidity and mortality.  Some results suggest that this phenomenon is driven by early 
adiposity rebound, the nadir of early childhood BMI. Children with early adiposity rebound are 
more likely to be obese or overweight in childhood and have symptoms of metabolic 
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syndrome..82-84  However, adiposity rebound may simply be a secondary phenomenon to 
children with higher BMIs having earlier rebounds.85      
B.5. Impact of Small Shifts in Distribution of Birth Weight 
 
 Most documented associations between environmental toxicant exposure and 
continuous health outcomes, such as IQ or birth weight, are typically clinically insignificant.  
While these decrements would not produce tangible effects at the individual level, they can have 
profound impacts on the tails of the distribution of IQ at the population level.  A well cited 
example comes from the literature on childhood lead exposure and IQ.  A 4-point decrease in 
mean IQ was observed in children with elevated blood lead levels (10 μg/dL) compared to 
children with low blood lead levels (2.4 μg/dL).86  Needleman and others have argued that a 
small shift in the mean of the distribution of IQ as a result of elevated blood lead levels can 
cause a 4-fold increase in the proportion of children classified as intellectually disabled 
(IQ<70).87  Bellinger has also argued the importance of this phenomenon using the example of 
blood pressure from the cardiovascular disease literature.88, 89  These studies show that 
exposure to low-level environmental toxins, like SHS, may cause small shifts in the mean of a 
continuous health outcome and lead to profound impacts on the tails of the distribution. 
C. Association between Prenatal Tobacco Smoke Exposure and Infant Weight 
C.1. Active Smoking and Infant Birth Weight 
 The US Surgeon General has reported that there is sufficient evidence to assume a 
causal relation between active maternal smoking during pregnancy and decreased birth 
weight.10   Several compounds found in tobacco smoke are implicated in delayed fetal growth 
and development.  Inhaled carbon monoxide is responsible for the production of 
carboxyhemoglobin which results in decreased rates of oxygen diffusion across the placenta.90-
92  Results from murine models suggest that nicotine exposure may result in delayed or altered 
embryonic implantation leading to growth deficits.93  Accumulation of cadmium in the placenta 
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may cause morphological and functional impairment of the placenta.94, 95  In addition, other 
tobacco smoke constituents may act through other mechanisms to produce decreased fetal 
growth and altered development.    
 Active smoking during pregnancy is associated with a 200-300 gram decrease in birth 
weight.10  Data from randomized trials of smoking cessation interventions offered to pregnant 
women have provided the best evidence of active smoking induced fetal growth deficits.15  
Observational studies have documented results similar to those from randomized trials. 
 Results from the Generation R study revealed a 1.75-times (95% CI: 1.20, 2.56) odds of 
LBW among women who smoked throughout pregnancy compared to non-smokers.96  The 
effect of smoking in late pregnancy was greatest among women who smoked >10 cigarettes per 
day (OR: 3.39; 95% CI: 1.45, 7.91).  In addition, the authors found a dose-response relation 
between the number of cigarettes smoked and decreases in mean birth weight.  Other studies 
have found similar decreases in mean birth weight and increased risk for LBW among women 
reporting active smoking.97-99   
 Several studies have used biomarkers of active smoking to examine and validate the 
relation between tobacco exposure and birth weight.  England et al. found that both self-
reported number of cigarettes smoked and urinary cotinine concentrations were associated with 
decreased birth weight.100, 101  Haddow et al. found that serum cotinine levels were more 
strongly correlated with birth weight than self-reported tobacco smoke exposure.102  Women 
who smoked > 25 cigarettes per day, representing the top 2.7% of women, had infants that 
weighed 289 grams less than non-smokers (bottom 68%).  Women with serum cotinine 
concentrations in the top 2.7% (>284 ng/mL) had infants that weighed 411 grams less than 
women in the bottom 68% of the serum cotinine distribution (<24 ng/mL).  This comparison is 
somewhat biased because women in the bottom 68% of the cotinine distribution included 
actively smoking women.  However, if serum cotinine levels in the lower range are associated 
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with decreases in birth weight, then the differences between women in the top 2.7% and non-
smokers is likely greater. 
 Ellard et al. also found that urinary cotinine levels provided a better estimate of smoking 
related deficits on birth weight than self-reported tobacco use (cigarettes/day) among 3,038 
pregnant women.103   A dose-response relation between tobacco smoke exposure and birth 
weight was only apparent when they used urinary cotinine levels.  In another cohort of 740 
pregnant women in Boston, a clearer dose-response relation between active smoking and birth 
weight emerged when urinary cotinine levels were used instead of maternal self-report of 
tobacco use (cigs/day).104  These results indicate that cotinine may provide a more accurate 
estimate of the dose of tobacco smoke constituents received by the mother and fetus, thus 
reducing exposure misclassification related to self-reported smoking. 
C.2. SHS Exposure and Infant Birth Weight 
 Many studies reporting an association between SHS exposure and birth weight have 
relied on self-report of paternal smoking or number of hours exposed at home or work.17, 99, 105-
107  As noted earlier, self-report of SHS exposure is problematic, resulting in a substantial 
proportion of women being misclassified as unexposed. 
 There is a reasonably consistent inverse relation between cotinine levels and birth 
weight (Table 1).  A meta-analysis of 11 studies with self-reported SHS exposure found a 28.5 
gram (95% CI: 16.2, 40.8 gram) decrement in birth weight among women exposed to at least 1 
hour of SHS per day compared to non-exposed women.5  Among the three studies using 
cotinine as a marker of SHS exposure, an 81.6 gram (95% CI: 36.7, 126.4 gram) deficit in birth 
weight was found among exposed women. 16, 102, 108  The authors of this meta-analysis also 
reported a 40% (95% CI: 1.0, 1.9) increased odds of LBW among SHS exposed women 
compared to non-exposed women.  If self-reported exposure does result in exposure 
misclassification, as this meta-analysis suggests, then using a biomarker is preferred since it will 
provide a more accurate estimate of the effect of SHS on fetal growth. 
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More recent studies have reported an inverse association between prenatal tobacco 
smoke exposure biomarkers and birth weight.  Kharrazi et al. conducted an analysis examining 
the relationship between 2nd trimester serum cotinine levels and birth weight among 2,777 
mother-infant dyads who were enrolled in the California alpha fetoprotein prenatal screening 
program in April of 1992.6  A one log10-unit increase in serum cotinine levels (i.e., 1 to 10 ng/mL) 
was associated with a 52.5 gram (95% CI: 22.9, 82.2 gram) decrease in birth weight.  A recent 
study in Washington DC collected two different salivary cotinine levels from 714 pregnant 
women during the 1st or 2nd trimester and before birth.109  Reductions in birth weight ranged from 
70 to 220 grams among women with higher salivary cotinine levels.  Their results suggest that 
salivary cotinine levels collected at birth are more strongly associated with reductions in birth 
weight; however the confidence intervals from the two sets of estimates substantially 
overlapped.   
C.3. Association between Prenatal Tobacco Smoke Exposure and Childhood Growth 
 A growing body of literature indicates that active prenatal tobacco smoke exposure 
increases the risk for overweight and obesity in childhood.  A recent meta-analysis of 14 studies 
found that active tobacco smoke exposure during pregnancy increased the risk of childhood 
overweight and obesity by approximately 50%.18  The results of this analysis did not suggest 
that confounding due to maternal anthropometry, sociodemographic factors, or child behaviors 
biased the estimated association between prenatal tobacco smoke exposure and the 
development of overweight or obese BMI. 
Using data from the Collaborative Perinatal Project, Chen et al. reported that children 
born to smokers were lighter and shorter than non-exposed children at birth.  Over the first 8 
years of life, they reported that exposed children were born shorter and lighter and grew heavier 
and remained shorter until 8 years of age.  Changes in these children’s growth patterns resulted 
in a 20% increased risk of overweight BMI at 8 years of age. 
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Animal models show that prenatal nicotine administration results in increased adiposity 
at birth,110 changes in postnatal growth trajectories,111 and metabolic changes consistent with 
diabetes and obesity.112  Some cross-sectional studies have observed an inverse association 
between active smoking and infant cord blood leptin levels,113, 114 while others have not.115, 116  
Control over infant and childhood growth is a complicated enterprise and is controlled by 
numerous hormonal systems,117 many of which could be altered by prenatal tobacco smoke 
exposure.    
 Less is known about the association between prenatal SHS exposure and childhood 
growth.  There are six studies that have examined the effect of pre- and early postnatal tobacco 
smoke exposures on childhood growth (Table 2).  There appears to be small decrements in 
height between 5 and 11 years of life associated with pre- and early postnatal SHS exposures.  
A study by von Kries et al. suggests that SHS exposures may be associated with increased 
odds for BMI later in life.118  Two studies have examined the association between prenatal SHS 
exposure and childhood BMI.  Leary et al. reported elevated BMI, total body fat, and truncal fat 
among 10-year old children whose mothers had a partner who smoked during pregnancy.21  
Oken et al. did not report any association between self-reported prenatal secondhand tobacco 
smoke exposure and BMI at 3 years of age.22   
 There are several limitations of the extant literature examining prenatal SHS exposure 
and childhood growth.  First, all but one study has relied on self-reported tobacco smoke 
exposures.119  Eskenazi and Bergmann’s study relied on older laboratory methodology that had 
an increased limit of detection for serum cotinine.  A valid biomarker of prenatal tobacco smoke 
exposures can reduce exposure misclassification of secondhand tobacco smoke exposures.9, 23, 
33  Third, prior studies have only had one postnatal measure of child size, thus there have been 
no studies examining the effect of SHS exposure on fetal growth trajectory.  The trajectory of 
growth may be as or more important than differences in weight or length at any given time point.  
Finally, almost all of these studies were conducted on women who gave birth several decades 
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ago.  Thus, the exposures experienced by these women are not relevant to contemporaneous 
women.   
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Table 1: Summary of studies examining the association between biomarkers of second hand 
smoke exposure and birth weigth 
Author (year) Location Birth 
Year(s) 
Sample 
Size 
Biomarker 
Type 
Timing of 
Exposure 
Measure 
Exposure 
Definition 
Birth Weight 
Decrement in 
Grams (95% CI) 
Rebaglato et al. 
(1995)108 
Spain 1989-1991 710 Saliva 3rd trimester 1.7-10 ng/mL vs. 
<0.5 ng/mL 
87 (1, 144) 
Eskenazi (1995)16 California, 
USA 
1964-1967 2,292 Serum 28 wks 2-10 ng/mL vs. 
<2ng/mL 
45 (-36, 126) 
Haddow et al. 
(1998)102 
Minnesota, 
USA 
1980s 1,231 Serum ?? 1-10 ng/mL vs. 
<0.5 ng/mL 
104 (35, 173) 
Hanke et al. 
(2001)120 
Poland 1997-1998 183 Serum 20-24 wks 2-10 ng/mL vs. 
<2ng/mL 
26 (CI not reported)
Jaakkola et al. 
(2001)121 
Finland 1996-1997 389 Hair Birth >4μg/g vs. 
<0.75 μg/g 
17 (-178, 145) 
Kharrazi et al. 
(2004)6 
California, 
USA 
1992 2,777 Serum 15-19 wks >0.235 ng/mL 
vs. <0.026 
ng/mL 
1 log10 unit 
39.7 (-16.3, 95.7) 
 
 
27 (-54, 1) 
Jedrychowski  
(2008)122 
Krakow, 
Poland 
2000-2003 467 Serum Cord 1 log10 unit 12.3 (-66.1, 90.7) 
El-Mohandes 
(2009)109 
Washington 
DC 
2001-2003 700 Salivary 1st/2nd 
trimester 
and birth 
Categorical 
(defined by 
authors) 
161 (-19, 341) 
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Table 2: Summary of studies examining association between pre- and postnatal tobacco smoke 
exposure and childhood growth 
Authors and Year Study 
Year 
Sample 
Size 
Exposures Exposure Outcome Remarks 
Rona and Chinn, 
1981 123  
1972 ~6500 Postnatal Number of smokers 
in the home 
Height at 
7 years 
Dose response between 
number of smokers and 
decrements in height. 
Rantakallio, 1983 
124 
Unknown Unknown Prenatal Fathers use of 
tobacco during 
pregnancy 
Height Decrements in height 
among women living with 
smoking partners. 
Rona, et al., 1985 
125 
1972 ~6500 Both Self-reported 
smoking of both 
parents 
Height at 
5-11 
years 
Decrements in height 
associated with postnatal 
exposure among pre-and 
postnatal exposed infants 
Chinn and Rona, 
1991 126 
1987 5002 Postnatal Total cigarettes 
smoked in the 
home 
Height at 
5-11 
years 
Small decrements in height 
Eskenazi and 
Bergmann, 1995 119 
1960s 2,622 Prenatal Serum cotinine and 
self-report 
Height at 
5 years 
Decrements in height 
associated with increasing 
serum cotinine 
Oken et al. 2005 22 1990s 746 Prenatal Self-report of active 
and secondhand 
tobacco exposure 
BMI and 
skinfold 
thickness 
at 3 years 
Increased BMI and skinfold 
thickness among children 
born to active smokers.  No 
association between SHS 
and BMI or skinfold 
thickness based on 
significance testing. 
Leary et al. 200 621 1991-
1992 
5689 Prenatal Self-report of active 
and secondhand 
exposures 
BMI and 
DXA at 10 
years 
Increased BMI, total fat, and 
truncal fat among prenatally 
exposed children.  
Magnitude of active 
associations larger, but less 
precise than secondhand 
associations. 
von Kries et al., 
2008 118  
2005 5,899 Both Self-report of 
maternal and 
paternal smoking 
BMI at 
mean age 
of 6 years 
Pre- and postnatal tobacco 
exposure associated with 
increased odds of 
overweight and obesity.   
 
 
 
 
 
 
 
 18
  
 
 
 
 
 
CHAPTER 3: METHODS 
 
A. Study Description 
 
A.1. Study Overview 
 
 The source of my data is an ongoing prospective birth cohort (Health Outcomes and 
Measures of the Environment [HOME] Study) that has been following 400 mothers and their 
children in the Cincinnati metropolitan area from early pregnancy to 5 years of age.  The 
purpose of the HOME study is to study the association between low-level environmental 
toxicants and childhood health outcomes.  A randomized trial is nested within this cohort to 
determine the efficacy of lead and injury hazard controls in the home. 
 Participants in the study were randomized to receive either injury prevention controls in 
the home or removal/remediation of lead hazards from the home.  Lead hazard controls 
included removal of deteriorated paint surfaces, encapsulation of lead hazards, and cleaning; all 
of which were conducted by certified and licensed contractors.  Mothers and infants in the injury 
reduction group did not receive interventions until the index child was 3 to 6 months old.  Data 
from the randomized trial will be used to examine the effect of lead hazard controls on children’s 
blood lead levels, intelligence, and behavioral problems in early childhood.   
A.2. Eligibility Criteria 
 Eligibility criteria for participation in the HOME study included:  
1. >18 years old 
2. 16 weeks (+ 3 weeks) gestation 
3. Living in a house, condominium, or apartment built before 1978; 
4. Cannot be diagnosed with or receive treatment or medications for seizures, 
thyroid disorders, bipolar/manic depression, schizophrenia, cancer, HIV or AIDS 
5. Have to live in and plan to deliver at participating OB practices in Brown, Butler, 
Clermont, Hamilton, or Warren counties.   
6. Cannot have plans to move outside of study area at the time of delivery. 
7. Must be fluent in English.   
 Participants were identified from 7 prenatal clinics associated with 3 hospitals in 
Cincinnati beginning in March of 2003.  Women who were identified as being < 18 years of age 
or residing in housing built after 1978 were excluded.  Recruitment letters were sent to the 
remaining eligible participants.  After receiving the recruitment letter, women were contacted by 
telephone to determine eligibility and invited to participate if eligible.  If they agreed to 
participate, women received informed consent in the mail to review before their next prenatal 
visit.  Once a woman agreed to participate and signed the informed consent form, they were 
met by study personnel at their next prenatal visit to collect biologic samples (blood, serum, 
urine and saliva) and baseline interview information.  A baseline home visit was scheduled for 
two to four weeks after the initial clinic visit to give the participant time to discuss the study with 
her family or friends.   
A.3. Study Sample 
 Between March of 2003 and January of 2006 a total of 8,371 women were identified 
from seven prenatal clinics associated with three hospitals.  We mailed letters to 5,512 women 
> 18 years of age who were living in a home built before 1978 to see if they were eligible and 
interested in participating in our study.   Among the 1,263 eligible women, 468 (37.1%) enrolled 
before the 19th week of pregnancy. Sixty-seven women (14.3%) dropped out before delivery, 
leaving 401 (85.7%) mothers who delivered 389 singletons, 9 children from sets of twins, and 3 
still-born children.   
 To target children at increased risk for lead exposure, there was an over-sampling of 
African American mothers.  African Americans comprise approximately 11% of the metropolitan 
Cincinnati population and the over-sampling resulted in the final sample consisting of 30% 
African Americans families.   
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B. Tobacco Smoke Exposures 
B.1 Self-Reported Tobacco Smoke Exposure 
Women were interviewed twice about secondhand and active tobacco smoke exposures 
for the periods between birth and 20 weeks (measured at 20 week home visit) and 20 weeks 
and birth (measured at 4 week postpartum visit).  The interviewer asked women the average 
number of cigarettes they smoked per day, the number of smokers living in the home, and the 
number of cigarettes smoked per day in the house.  I classified exposure during each time 
period as unexposed, secondhand exposure, and active exposure.   
B.2. Prenatal Biomarkers of Tobacco Smoke Exposure 
 Serum biomarkers of tobacco smoke exposure were collected from women three times 
during pregnancy at 16 and 26 weeks gestation and within 24 hours of birth.  Meconium 
samples were collected during the birth hospital stay.   
Mothers provided three serum samples during pregnancy using a standardized 
venipuncture technique during routine clinic visits around 16 and 26 weeks gestation and within 
24 hours of birth.  Serum samples were stored at -20oC until they were shipped to Centers for 
Disease Control and Prevention (CDC) for analysis.   
 Meconium specimens were collected from infant diapers.  Hospital staff were asked to 
attach cellulose fiber inserts to the inside of the infants diapers.  After the diaper was soiled, the 
diaper was stored in a labeled plastic bag.  If meconium was present before the infant was put 
in a diaper, hospital staff collected the meconium in labeled storage containers and stored them.  
At least 5 meconium stools per neonate were obtained during the birth hospital stay.  Meconium 
samples for each infant were pooled prior to storage.  Both diapers and collection containers 
were stored at -20oC until they were transported to the laboratory.  All other biological samples 
were also stored at -20oC until they were transported to the laboratory.   
 Serum and meconium samples were delivered to the Biomarker Laboratory Core at 
Cincinnati Children’s Hospital and Medical Center by project staff at the end of each collection 
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day.  Meconium and maternal serum samples collected for cotinine analysis were sent to the 
CDC for analysis.   
B.2.1. Laboratory Analysis and Quality Control 
 Levels of cotinine were measured in serum using a previously described sensitive 
atmospheric-pressure ionization, tandem mass spectrometric method developed by Dr. Pirkle at 
the CDC.42  High performance liquid chromatography-tandem mass spectrometry (HPLC-MS) is 
considered the gold standard to measure cotinine with the highest accuracy and precision.  The 
limit of detection (LOD) for this assay was 0.015 ng/mL and had a coefficient of variation (CV) 
ranging from 3-4% at high concentrations (1 ng/mL) to 10% at low concentrations (100 pg/mL).   
Approximately 0.5 grams of meconium were digested at room temperature in potassium 
hydroxide, which resulted in a free-flowing liquid.  The digested material was then liquid-liquid 
extracted with methylene chloride and methylene chloride and ethanol.  The solution was then 
back-extracted into hydrochloric acid and applied to a CleanScreen DAU column and processed 
as described by Ostrea et al.47  HPLC-MS was then used to quantify the concentration of the 
nicotine NIC, COT, and 3HC using deuterated standards.  Our laboratory results indicate that 
this method is mild enough to avoid metabolite decomposition while ensuring a high metabolite 
recovery.  The LOD for these three compounds was 0.946 ng/gm for NIC, 0.070 ng/gm for COT, 
and 0.092 ng/gm for 3HC.  Each analytical run included two blank samples and a low and high 
concentration quality control (QC) sample.  The low-concentration QC samples had a CV 
between 10 and 30% while the high-concentration QC samples had a CV between 3 and 20%. 
C. Infant and Childhood Growth Outcomes 
C.1. Infant Birth Weight and Gestational Age 
 Trained research staff abstracted gestational age, birth weight from hospital charts and 
medical records.  Gestational age was derived from last menstrual period (LMP), ultrasound, or 
Ballard scores.  
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C.2. BMI Measurements 
 Weight and length were measured at 4 weeks, 1, 2, and 3 years of age.  Values were 
derived from the mean of 3 separate measurements that were taken in our study clinic.  Length 
was measured with a length board at 4 weeks and 1 year and a stadiometer at 2 and 3 years.  
Weight was measured using an infant scale at 4 weeks and 1 year and a pediatric scale at 2 
and 3 years.  Body Mass Index (BMI), a measure of adiposity,127, 128   was calculated by dividing 
weight in kilograms by height in meters squared.  Age and sex-specific weight, height, and 
weight-for-height z-scores were derived from CDC growth charts.129  Children were classified as 
overweight at 2 and 3 years of age if their BMI was greater than the 85th percentile for their age 
and sex.   
C.3. Confounders 
 I used directed acyclic graphs (DAGs) to examine the role of potential confounders in 
both of my aims (Greenland and Brumback 2002; Greenland et al. 1999) (Figures 1 and 2).  I 
did not adjust for confounding variables in the analysis examining the utility of meconium as a 
biomarkers since any confounding would be due to unmeasured genetic or metabolic factors 
(Figure 1).   
Table 3 outlines the details of my exposure, outcome, and confounding variables for 
these 2 aims.  Confounders for Aim 1 and 2 included demographic, maternal, and perinatal 
factors.  Demographic information, including maternal age, education, race, and marital status 
collected from interviews.   Maternal and perinatal factors included depression, parity, and 
maternal weight and height.  Maternal depression was assessed using the Beck Depression 
Inventory-II (BDI-II) which was administered during a home visit at approximately 20 weeks.130    
Parity was abstracted from medical records.  Maternal weight (in kg) and height (in cm) were 
collected at the initial clinic visit at 16 weeks gestation.   
Additional confounders were included for my Aim 2 analysis to capture confounding 
related to childhood activity and nutrition.  These included household income which was 
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collected at the first prenatal care visit.  Breast feeding duration was used as a proxy for early 
life nutrition.  Breast feeding was assessed every 3 months using a phone or in-person interview 
that asked the mothers how much breast milk they fed their infants in each of the past 3 months.   
I also examined the potential for residual confounding due to SES status.  I attempted to 
control for this by including Home Observation and Measures of the Environment (HOME) 
Inventory scores in my statistical models.  The HOME Inventory is a semi-structured interview 
that assesses the quality of the caregiving environment 131, 132 and was administered by trained 
interviewers during a home visit when the child was 1 year old.  I did not adjust for gestational 
age at delivery since it lies on the causal pathway between prenatal tobacco smoke exposure 
and infant and childhood size.   
C.4. Ethical Considerations  
 The Institutional Review Boards (IRB) of the University of North Carolina-Chapel Hill, 
Cincinnati Children’s Hospital Medical Center, and CDC approved this study.  The University Of 
Cincinnati College Of Medicine IRB was involved in the oversight of this study in the early 
stages of planning and implementation.  All mothers provided written informed consent for 
themselves and their children prior to enrollment in the study.  The informed consent signed at 
enrollment provided consent for follow-up, sample collection, and examinations until the child’s 
3rd birthday.   
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 Figure 1: DAG representing the association between prenatal tobacco smoke exposure and 
meconium tobacco smoke metabolite concentrations.   
Prenatal Tobacco 
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Maternal Serum 
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Concentration 
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Concentrations 
Fetal MetabolismMaternal Metabolism 
Shared Metabolism 
Genes 
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Unknown Factors 
Effecting Metabolism 
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Figure 2: DAG representing the association between prenatal tobacco smoke exposure and 
childhood growth.   
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*-The top part of the DAG is reduced to the prenatal tobacco smoke and child size boxes for 
simplicity below. I assume that each variable’s arrow will terminate at each size measurement. 
U1-Represents unknown SES factor that represents nutrition and activity factors.   
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 Table 3: HOME Study Variables Used in Analyses 
Variable Source Details Coding Aim 
Outcome Variables     
  Birth Weight Med Records In grams  Continuous 1 and 2
  Birth Length Med Records In cm Continuous  1 and 2
  Birth Head Circumference Med Records In cm Continuous  1 and 2
  Weight Anthropometrics at 
4 weeks, 1, 2, and 3 
years 
In kg Continuous 2 
  Length/Height Anthropometrics at 
4 weeks, 1, 2, and 3 
years 
In cm   Continuous 2 
  BMI Kg/m2 Derived for data at 
birth, 4 weeks, 1, 2, 
and 3 years 
Continuous 
 
 
Categorical: 
Overweight: >85th age 
and sex standardized 
percentile 
  
Normal weight: <85th 
age and sex 
standardized 
percentile 
2 
Exposure Variables     
  Prenatal Serum Cotinine 16 and 26 week 
appointment, birth 
hospital stay 
In ng/mL Log10 transformed 
continuous.  
Categorical as no 
exposure, passive, and 
active 
1 and 2
  Postnatal Serum Cotinine 12 Months In ng/mL Log10 transformed 
continuous. 
2 
  Meconium Cotinine Birth hospital stay In ng/gm Log10 transformed 
continuous.  
Categorical as no 
exposure, passive, and 
active 
1 
  Self-Reported Tobacco   
  Exposure 
20-week prenatal 
home visit and 4-
week postpartum 
visit 
Number of smokers in 
the home. 
 
Number of cigarettes 
smoked per day in 
the home 
 
Any active smoking 
as number of 
cigarettes per day. 
Categorize as 
unexposed, second 
hand exposure, active 
exposure.   
  
1 
Confounders     
  Maternal Age Demographics In years <25, 25-34, >35 2 
  Maternal Race Demographics  Non-Hispanic White, 
non-Hispanic Black, 
2 
and other 
Variable Source Details Coding Aim 
Confounders (cont)     
  Maternal Education Demographics In years <12, 12, and >12 2 
  Marital Status Demographics  Married and non-
married/living alone 
2 
  Child Sex Birth records  Male vs. female 2 
  Maternal weight and height Anthropometrics at 
16 week visit 
In kg and cm Continuous 2 
  Depression Beck Depression 
Inventory 
 Mild or minimal vs. 
moderate or severe 
2 
  Alcohol use Interview  Any or none 2 
  Parity Birth records  0, 1, and >1 2 
  Breast feeding Quarterly surveys In years Time varying as the 
number of years of 
feeding since the last 
anthropometric 
measurement 
2 
  Household Income Demographics In dollars <$40K, $40K-<$80K, 
and >$80K 
2 
  Gestational Age Medical Records In weeks Continuous Variable 1 
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D. Statistical Analyses 
D.1. Statistical Analyses for Aim 1: Relationship between Serum and Meconium 
Biomarkers of Tobacco Smoke and Their Association with Infant Birth Weight 
Aim 1: Examine the utility of meconium nicotine, cotinine, and OH-cotinine as a biomarker of 
prenatal tobacco smoke exposure. 
Sub Aim 1.1: Determine if three serial serum cotinine concentrations and self-reported 
tobacco smoke exposures are positively associated with meconium tobacco smoke 
metabolites.   
Sub Aim 1.2: Determine if meconium tobacco smoke metabolites represent cumulative 
exposure to gestational tobacco smoke.     
Sub Aim 1.3: Compare the associations between serum and meconium biomarkers of 
prenatal tobacco smoke exposure and infant birth weight.   
 
Aim 1 examined the utility of meconium tobacco smoke metabolites as a biomarker of 
prenatal tobacco smoke exposure.  Statistical analyses were conducted on women who had at 
least 2 prenatal serum cotinine measurements and whose infants had a valid meconium 
measurement.  Some analyses were further restricted to women with all 3 prenatal serum 
cotinine measurements or to women who completed both self-reports of prenatal tobacco 
smoke exposure.  I started the statistical analysis by comparing women and infants with 
complete meconium, self-report and serum data to women with missing data.   
I corrected for the right-skewed distribution of serum and meconium metabolite 
concentrations using the log10-transformation in analyses using continuous variables.  In 
analyses involving meconium metabolite concentrations, results are presented for each 
metabolite (NIC, COT, and 3HC), as well as the sum of the three metabolites.   
I created several measures of cumulative prenatal tobacco smoke exposure using either 
prenatal serum cotinine concentrations or self-reported tobacco smoke exposure (Table 4).  
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First, I created a summary variable of women’s self-reported prenatal tobacco smoke exposure 
among women with both tobacco smoke exposure interviews and infant meconium metabolite 
concentrations.  This five category variable counted the number of periods that a woman had 
secondhand (0, 1, or 2 periods) or active (1 or 2 periods) tobacco smoke exposure.  Women 
with 1 period of secondhand exposure could not have active exposure in the other period, 
whereas women with active exposure in 1 period could have secondhand or no reported 
tobacco smoke exposures in the other period.     
Next, I used the mean of 2 or 3 individual serum cotinine measurements to create 
continuous and categorical summaries of women’s prenatal tobacco smoke exposure between 
16 weeks gestation and birth.  I used categories of unexposed, (<LOD), secondhand exposure 
(LOD – 3 ng/mL), or active exposure (> 3 ng/mL). 
Among women with all 3 serum cotinine and meconium measurements, I further 
quantified cumulative exposure to prenatal tobacco smoke by creating a summary variable that 
described the number of prenatal serum measurements that a woman was exposed to 
secondhand or active tobacco smoke.  This seven category variable counted the number of 
measurements that a woman had secondhand (0, 1, 2, or 3) or active (1, 2, or 3) serum cotinine 
concentrations.  Women in any of the secondhand categories could not have active exposure at 
their other measurements, while women in the active categories could have secondhand 
exposure or no exposure at their other measurements. 
Finally, I investigated whether the timing of the serum measurements confounded the 
association between the number of secondhand or active serum cotinine measurements and 
meconium NIC concentrations.  I did this by creating a 13 category variable that summarized 
the number and timing of secondhand and active serum measurements for the 16 week, 26 
week, and birth serum cotinine measurement.  I limited this analysis to NIC concentrations since 
they were detected most frequently and because the results with NIC were similar to COT and 
3HC.   
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I calculated the geometric mean and standard deviation (GM and GSD) of meconium 
metabolite concentrations according to self-reported and serum cotinine concentration 
categories.  I also calculated the proportion of infants with detectable meconium tobacco smoke 
metabolite concentrations according to self-reported and serum cotinine categories.   
I used Locally Weighted Scatterplot Smoothing (LOESS) to graphically examine the 
relationship between the mean serum cotinine concentration and meconium tobacco smoke 
metabolite concentrations.  LOESS uses locally weighted polynomials to fit subsets of data 
using ordinary least squares regression, giving more weight to points near the exposure value 
whose response is being estimated and less weight to points farther away.133   
 LOESS was used to examine the shape of the relationship between serum and 
meconium biomarker concentrations and infant size and gestational age.  I used linear 
regression to estimate the association between log10-transformed serum and meconium 
biomarker concentrations and infant birth weight.  I also estimated the association between 
each individual serum cotinine concentration (16 week, 26 week, and birth) and infant weight 
since many studies only can collect biomarkers at one time during pregnancy.  Future 
investigators would be interested in comparing biomarkers that could be across the duration of 
pregnancy.  I compared the magnitude and precision of meconium estimates to estimates using 
mean serum cotinine concentrations and estimates from the prior literature.   
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Table 4: Summary measures of prenatal tobacco smoke exposure using self-report or serum 
biomarkers 
 Categories 
Summary Self-Report 1: No exposure in either period 
2: Passive exposure in 1 period 
3: Passive exposure in both periods 
4: Active exposure in 1 period 
5: Active exposure in both periods 
Mean Serum Cotinine 1: Unexposed (<LOD) 
2: Secondhand (LOD – 3ng/mL) 
3: Active (>3ng/mL) 
Cumulative Serum Cotinine 1: Unexposed all 3 measures 
2: Passive exposure in 1 measure 
3: Passive exposure in 2 measures 
4: Passive exposure in 3 measures 
5: Active exposure in 1 measure 
6: Active exposure in 2 measures 
7: Active exposure in 3 measures 
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D.2. Statistical Analysis for Aim 2: Association between Prenatal Tobacco Smoke 
Exposure and Child Growth Over the First Three Years of Life 
Aim 2: Estimate the association between prenatal secondhand and active tobacco smoke 
exposure and childhood BMI in the first three years of life. 
Sub Aim 2.1: Compare the association between self-report and serum biomarkers of 
prenatal tobacco smoke exposure and BMI over the first three years of life. 
 
 Statistical analyses for Aim 2 began by comparing the demographic and exposure 
distributions of women-child dyads with missing and complete exposure and covariate data.  
Analyses included women with at least 2 prenatal serum cotinine measurements and complete 
covariate data.   
Prenatal tobacco smoke exposure was quantified using the mean of at least 2 serum 
cotinine measurements and two self-reported measurements.  I classified prenatal exposure 
into categorical and continuous variables.  In categorical analyses using serum cotinine 
concentrations I classified women as unexposed (<0.015 ng/mL), secondhand exposure (0.015 
to 3 ng/mL), and active exposure (>3 ng/mL).  The threshold of 3 ng/mL was chosen based off 
of recent analyses of the National Health and Nutrition Examination Survey (NHANES) that 
found the previous threshold of 15 ng/mL resulted in a substantial proportion of smokers being 
classified as non-smokers.134  I also created a continuous log10-transformed serum cotinine 
variable.  All continuous cotinine analyses were repeated among women with no active tobacco 
smoke exposure during pregnancy (e.g., all 3 serum cotinine measurements <3 ng/mL).  Self-
reported prenatal tobacco smoke exposures were classified as unexposed for both periods of 
pregnancy, SHS exposure for one or two periods, and active exposure for one or two periods 
(could have SHS or no exposure in other period). 
I started my analyses by cross-classifying self-reported and serum cotinine categories of 
prenatal tobacco smoke exposure.  I assessed linearity between log10-transformed mean 
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prenatal and postnatal serum cotinine concentration and children’s BMI at birth, 4 weeks, 1, 2, 
and 3 years using Locally Weighted Scatter Plot Smoothing (LOESS) analysis.  LOESS uses 
locally weighted polynomials to fit subsets of data using ordinary least squares regression, 
giving more weight to points near the value whose response is being estimated and less weight 
to points further away 133  
 Linear mixed models were used to examine the association between BMI and prenatal 
tobacco smoke exposure because of within-subject correlation of repeated measurements.  
Model construction began by modeling the association between weight, length, or BMI as a 
function of time (in years) since birth (birth coded as 0).  Time was modeled with a linear, 
square, and cubic term.  I explored using subject specific intercepts and time slope coefficients.  
However due to the homogeneity of growth trajectories in my sample the model fit better without 
these additional parameters.  I included interactions terms between prenatal tobacco smoke 
exposure variables and time to allow the association between prenatal tobacco smoke exposure 
and childhood BMI to change at each follow-up visit.   
 :Logistic regression with generalized estimating equations was used to estimate the 
odds of overweight BMI at 2 or 3 years among by prenatal tobacco smoke exposure category 
(self-report or serum cotinine). 
I compared estimated and compared the association between prenatal tobacco smoke 
exposure and childhood BMI using self-report or serum cotinine biomarkers.  I estimated the 
precision of estimates using the confidence limit difference.135 
 All analyses were adjusted for maternal age, education, race, marital status, child sex, 
depression at 20 weeks gestation, parity, household income, breast feeding length and maternal 
weight/height/BMI.  Breast feeding length was a time varying covariate that was coded as the 
number of weeks of breast feeding since the last child size measurement.   
 Several secondary analyses were conducted.  First, trajectories of childhood growth 
were examined using weight, height, and weight-for-height z-scores.  Weight, height, and 
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weight-for-height z-scores were computed using publicly available software from the National 
Centers for Health Statistics (NCHS).  I estimated the mean weight, height, and weight-for-
height z-score at birth and 1, 2, and 3 years of age according to prenatal tobacco smoke 
exposure category as well as the change in weight, height, or weight-for-height z-score among 
children with prenatal SHS or active tobacco smoke exposures compared to unexposed children 
(Appendix 1). 
 Second, I examined whether weight or height were responsible for associations between 
prenatal tobacco smoke exposure and BMI.  I constructed linear mixed models as described 
above, but used continuous weight (in kg) or height (in cm) as the outcome in additional models 
(Appendix 2).  Third, I included HOME Inventory scores in my statistical models to control for 
residual SES confounding.  Finally, I restricted my analyses to the mothers and infants who 
completed all 4 follow-up visits to determine whether attrition biased my results (Appendix 3). 
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CHAPTER 4: RESULTS 
 
A. Manuscript 1: Biomarkers of Prenatal Tobacco Smoke Exposure: The Correlation 
between Serum and Meconium and Their Association with Infant Birth Weight  
A.1. Introduction 
Fetal meconium is formed beginning in the 13th week of gestation from swallowed 
amniotic fluid, shed epithelial cells, and intestinal secretions.24  Because meconium is 
metabolically inert, concentrations of drugs and other toxicants are thought to represent 
cumulative gestational exposure over the latter two-thirds of pregnancy.  Ostrea and colleagues 
reported that meconium is a sensitive marker of gestational drug use in high-risk populations.25, 
47, 136  Others suggest that meconium may be a more sensitive matrix to measure gestational 
exposure to pesticides compared to maternal and infant hair and blood.137, 138    
Several studies have detected and quantified tobacco smoke metabolites including 
nicotine (NIC), cotinine (COT), and trans-3’-hydroxycotinine (3HC) in infant meconium 
samples.25, 27, 28, 48, 139  In humans, approximately 70 to 80% of NIC is metabolized into COT and 
50% of COT is metabolized into 3HC.140  Results from these studies indicate that NIC, COT, 
and 3HC concentrations are correlated with maternal report of tobacco smoke exposure.  
However, prior studies have been limited by use of self-reported or biomarkers of tobacco 
smoke exposure at birth to represent gestational exposures or have had few women with 
secondhand tobacco smoke (SHS) exposure.25, 27, 29  To date, no studies have used serial self-
reported or biomarkers of prenatal tobacco smoke exposure to determine if meconium tobacco 
smoke metabolites reflect the intensity and duration of prenatal tobacco smoke exposure.   
 Only two studies have examined the association between meconium tobacco smoke 
metabolite concentrations and childhood health outcomes.26, 28  Gray and colleagues reported 
decrements in birth weight, length, and head circumference among women with detectable 
meconium tobacco smoke metabolite concentrations.  Nuesslein et al. found a positive 
association between meconium cotinine concentrations and risk of respiratory infections in the 
first year of life.  Both studies were relatively small and did not have other biomarkers of tobacco 
smoke exposure that allowed for comparison to meconium results.   
 We used data from the Health Outcomes and Measures of the Environment (HOME) 
Study to examine whether serial self-reported and serum biomarkers of prenatal tobacco smoke 
exposure were associated with meconium tobacco smoke metabolite concentrations.141  We 
also examined whether meconium tobacco smoke metabolites represent cumulative gestational 
exposure to tobacco smoke.  Finally, we evaluated whether the two biomarkers (meconium and 
serum) would produce similar results when investigating the association between prenatal 
tobacco smoke exposure and infant birth weight.   
A.2. Methods 
A.2.1. Study Sample 
 We used data collected from mothers and their infants participating in the HOME Study, 
an ongoing prospective birth cohort in the Cincinnati metropolitan area designed to examine 
low-level environmental toxicant exposure and the efficacy of injury and lead hazard controls in 
the home.  From in March of 2003 to January 2006, women were identified from seven prenatal 
clinics associated with three hospitals.  Eligibility criteria for the study included: <19 weeks 
gestation; > 18 years old; living in a house built before 1978; negative HIV status; and not taking 
medications for seizure or thyroid disorders.  We mailed letters to 5,512 women > 18 years of 
age who were living in a home built before 1978 to see if they were eligible and interested in 
participating in our study.  Additional eligibility criteria included: 13-19 weeks gestation at study 
enrollment; living in Brown, Butler, Clermont, or Warren counties, intention to continue prenatal 
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care and deliver at collaborating obstetric practices,  HIV negative; and not receiving seizure, 
thyroid, or chemotherapy/radiation medications.  Of the 1,263 eligible women, 468 enrolled in 
our study.  Our analyses were restricted to singleton infants.    
A.2.2.Tobacco Smoke Measurements 
A.2.2.1. Self-Reported Exposure 
 Women were interviewed twice about secondhand and active tobacco smoke exposures 
for the periods between conception and 20 weeks (measured at 20 week home visit) and 20 
weeks and birth (measured at 4 week postpartum visit).  Trained interviewers asked the women 
the average number of cigarettes they smoked per day, the number of smokers living in the 
home, and the number of cigarettes smoked per day in the home for each time period.  We 
classified the woman’s exposure status during each time period as unexposed, exposed to 
secondhand tobacco smoke, and exposed to active tobacco smoke.   
A.2.2.2. Serum and Meconium Biomarkers of Exposure 
Women provided three serum samples at 16 weeks gestation, 26 weeks gestation, and 
within 24 hours of birth.  All samples were stored at -20oC until they were transported to the 
Centers for Disease Control and Prevention (CDC) laboratory for analysis, where they were 
stored at < -20oC.  Serum samples were assayed for cotinine, a biomarker of nicotine exposure, 
using high performance liquid chromatography tandem mass spectroscopy (HPLC-MS/MS).42  
The limit of detection (LOD) for this assay was 0.015 ng/mL and had a coefficient of variation 
(CV) ranging from 3-4% at high concentrations (1 ng/mL) to 10% at low concentrations (100 
pg/mL).   
 Meconium specimens were collected from infants during their hospital stay by placing 
cellulose fiber inserts inside infant diapers.  After it was soiled, the diaper and insert were stored 
in a labeled plastic bag in a refrigerator.  Meconium samples for each infant were pooled and 
subsequently stored at -20o C until transported to CDC laboratories where they were stored < -
20oC.   
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 Briefly, for this analysis approximately 0.5 grams of meconium were digested at room 
temperature in 3 mL of 5N potassium hydroxide containing the internal standards.  The digested 
material was extracted with methylene chloride and ethanol, back-extracted into hydrochloric 
acid, neutralized, buffered, and applied to a CleanScreen DAU column which was processed 
essentially as described by Ostrea et al.47  HPLC-MS/MS was used to quantify the 
concentration of the NIC, COT, and 3HC relative to the deuterated internal standards.  The LOD 
for these three compounds was 0.946 ng/gm for NIC, 0.070 ng/gm for COT, and 0.092 ng/gm 
for 3HC.  Each analytical run included two blank samples and a low and high concentration 
quality control (QC) sample.  The low-concentration QC samples had a CV between 10 and 
30% while the high-concentration QC samples had a CV between 3 and 20%. 
A.2.3. Infant Birth Weight and Covariates 
 Infant birth weight (in grams) was abstracted from hospital medical records and was 
analyzed as a continuous variable.  Maternal age, race, education, and martial status were 
gathered at the first prenatal care visit.  Maternal depression was assessed using the Beck 
Depression Inventory-II (BDI-II) which was administered during a home visit at approximately 20 
weeks.130  Parity was obtained from maternal medical records.  Maternal weight (in kg) was 
collected at the initial clinic visit at 16 weeks gestation.  
A.2.4. Statistical Analysis 
We conducted our statistical analysis in two stages.  First we examined the relationship 
between the various self-report and biomarkers of prenatal tobacco smoke exposure.  Then, we 
examined and compared the association between meconium and serum biomarkers of tobacco 
smoke exposure and infant birth weight.   
We started our statistical analysis by comparing women and infants with complete 
meconium, self-report, serum, and birth weight data to women with missing data.  We corrected 
for the right-skewed distribution of serum cotinine and meconium tobacco smoke metabolite 
concentrations using the log10-transformation in analyses using continuous variables.  Serum 
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and meconium cotinine values <LOD were randomly imputed from the left tail of the log10-
normal distribution.142   
A.2.5.1. Relationship between Self-Report and Biomarkers of Tobacco Smoke Exposure 
We compared the methods of classifying tobacco smoke exposures among mother-
infant pairs with at least two prenatal serum cotinine measurements and a valid meconium 
measurement available.  We created several measures of cumulative prenatal tobacco smoke 
exposure using either self-reported tobacco smoke exposure or prenatal serum cotinine 
concentrations.   
First, we created a summary variable of self-reported prenatal tobacco smoke exposure 
over the course of pregnancy.  This five category variable reflected the level and duration of 
exposure: unexposed, SHS exposure in one period, SHS exposure in both periods, active 
exposure in one period (the other period was unexposed or SHS exposure), and active 
exposure in both periods.       
Next, we compared the three serum cotinine measurements from each woman.  
Because they were highly correlated (R~0.7-0.9), we calculated the avaialble serum cotinine 
measurements to create a continuous summary measure women’s prenatal tobacco smoke 
exposure between 16 weeks gestation and birth.  Form this, we also created categories of 
unexposed (<LOD), secondhand exposure (LOD – 3 ng/mL), and active exposure (> 3 ng/mL) 
over the course of pregnancy.  The threshold of 3 ng/mL for active smoking was chosen based 
on results from the 1999-2004 National Health and Nutrition Examination Survey which 
compared self-reported smoking status and serum cotinine levels among a representative 
sample of the US population.134 
Among women with all three serum cotinine and meconium measurements, we further 
quantified cumulative exposure to prenatal tobacco smoke by creating a summary variable that 
described the number of prenatal serum measurements that a woman was exposed to 
secondhand or active tobacco smoke.  This seven category variable counted the number of 
 40
measurements that a woman had serum cotinine concentrations indicative of secondhand (zero, 
one, two, or three) or active (one, two, or three) tobacco smoke exposure.  Women in any of the 
secondhand categories could not have had active exposure at another time point, while women 
in the active categories could have had another serum measurement indicative of secondhand 
or no exposure. 
Finally, we investigated whether the timing of the serum measurements influenced the 
association between the number of serum cotinine measurements indicative of secondhand or 
active tobacco smoke exposure and meconium NIC concentrations.  We did this by creating a 7 
category variable that summarized the number and timing of serum cotinine concentrations 
consistent with secondhand and active tobacco smoke exposure at 16 weeks and birth.  We 
limited this analysis to NIC concentrations because NIC was detected most frequently and the 
results with NIC concentrations were similar to those using COT and 3HC concentrations.   
We calculated the geometric mean (GM) and corresponding 95% confidence interval 
(CI) of meconium tobacco smoke metabolite concentrations according to self-reported and 
serum cotinine concentration categories described above.  We also calculated the proportion of 
infants with detectable meconium tobacco smoke metabolite concentrations according to self-
reported or serum categories.   
A.2.5.2. Association between Biomarkers of Prenatal Tobacco Smoke Exposure and 
Infant Birth Weight 
The second stage of our analysis examined the association between biomarkers of 
tobacco smoke exposure and infant birth weight.  We chose to examine birth weight because 
there is a well-established inverse relationship between serum cotinine concentrations and 
infant birth weight.5, 6, 102, 108, 143  First, we analyzed the shape of the association between log10-
transformed serum and meconium cotinine concentrations and birth weight using LOESS.144   
 Next, we estimated and compared the associations between continuous prenatal serum 
cotinine and meconium tobacco smoke metabolite concentrations and infant birth weight using 
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linear regression.  Coefficients from these analyses represent the mean change in infant birth 
outcome for a 10-fold increase in mean prenatal serum cotinine or meconium tobacco smoke 
metabolite concentration.  We also estimated the associations using meconium tobacco smoke 
metabolites and individual serum cotinine concentrations.  In addition, we examined the 
association between categorical serum and meconium tobacco smoke metabolite 
concentrations and infant birth weight.  Serum cotinine concentrations were categorized using 
the thresholds described above.  Several different meconium tobacco smoke metabolite 
concentrations were used to discriminate secondhand from active tobacco smoke exposure.  
We compared the results for various exposure methods because many cohorts only have the 
resources to collect one exposure measurement.  We examined the precision of the estimates 
by calculating the confidence limit difference (CLD) for each point estimate.135 
 In all of the analyses examining the association between prenatal tobacco smoke 
exposure and infant birth weight, we adjusted for confounders identified using a directed acyclic 
graph (DAG).145  DAGs are a better method to assess the role of confounding variables 
compared to change in estimate and significance testing approaches.146 Based on our DAG, we 
all models included maternal age (18-24, >35, and 25-34 years), maternal education (<12, 12, 
and >12 years), maternal race (non-Hispanic white, non-Hispanic black, and other), marital 
status (married vs. non-married), depression (minimally depressed [BDI-II score <14], mildly 
depressed [BDI-II Score 14-19], and moderately or severely depressed [BDI-II Score >20]), and 
maternal weight (in birth weight model) or height (in birth length model).  We did not adjust for 
gestational age since it was an intermediary on the causal pathway between prenatal tobacco 
smoke exposure and infant birth weight. 
Ethical Considerations 
 The Institutional Review Boards (IRB) of the University of North Carolina-Chapel Hill, 
Cincinnati Children’s Hospital and Medical Center, and CDC approved this study.  The 
Cincinnati Children’s Hospital and Medical Center IRB was involved in the oversight of this 
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study.  All mothers provided written informed consent for themselves and their children prior to 
enrollment in the study. 
A.3. Results 
 Of the 468 women who enrolled in our study, 67 dropped out before delivery.  We 
excluded 9 children from sets of twins and 3 still-born infants, leaving 389 infants.  A total of 326 
women and infants (83.8%) had at least two prenatal serum measurements and a meconium 
measurement available, many (n=284, 73.0%) had all three prenatal serum measurements and 
a meconium measurement.  Complete self-reported tobacco smoke exposure and meconium 
data was available for 316 (81.2%) women.  Women with complete data were better educated, 
non-Hispanic white, married, and 25-34 years of age compared to women with incomplete data 
(Table 5).     
A.3.1. Relationship between Self-Report and Biomarkers of Tobacco Smoke Exposure 
NIC, COT, and 3HC were detected in 80.1, 69.1, and 56.7% of infant meconium 
samples, respectively; 90.2% of samples had at least one detectable metabolite.  Sixty-one 
percent of women had mean serum cotinine concentrations > LOD and 88.9% had at least one 
detectable serum cotinine concentration between 16 weeks gestation and birth.  Geometric 
mean meconium tobacco smoke metabolite concentrations were highest for NIC (GM: 2.40 
ng/gm; 95% CI: 2.08, 2.78) and lower for COT (GM: 0.19 ng/gm; 95% CI: 0.15, 0.24) and 3HC 
(GM: 0.17 ng/gm; 95% CI: 0.13, 0.23).  Seventy-five percent of women with mean serum 
cotinine concentration <LOD gave birth to infants with at least one detectable meconium 
tobacco smoke metabolite.    
Meconium tobacco smoke metabolite concentrations were highly correlated with each 
other: NIC and COT (Pearson R=0.79), NIC and 3HC (Pearson R=0.72), and COT and 3HC 
(Pearson R=0.85).  Meconium and serum metabolite concentrations were also highly correlated: 
NIC (Pearson R=0.59), COT (Pearson R=0.72), and 3HC (Pearson R=0.71).  The CVs for our 
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meconium tobacco smoke metabolite assays (10-30%) were approximately 3 times higher than 
the CVs for our serum metabolite assays (3-10%). 
Self-reported tobacco smoke exposures were positively associated with mean and 
detectable meconium tobacco smoke metabolite concentrations (Table 6).  Compared to 
unexposed infants, women self-reporting SHS exposure gave birth to infants with slightly higher 
meconium nicotine concentrations and those reporting active smoking gave birth to infants with 
meconium nicotine concentrations 1 to 3 orders of magnitude higher.  Meconium COT and 3HC 
concentrations were similar among women with self-report of secondhand or no tobacco smoke 
exposures, but higher among self-reported active smokers.   
Infant meconium tobacco smoke metabolite concentrations were greater when mother’s 
mean serum cotinine concentrations indicated secondhand and active tobacco smoke exposure 
rather than no exposure (Table 6).  All three meconium tobacco smoke metabolites were 
detected in essentially all infants born to women with mean serum cotinine concentrations > 3 
ng/mL.   
Meconium tobacco smoke metabolite concentrations increased with the number of 
serum cotinine measurements indicative secondhand or active tobacco smoke exposure (Table 
6).  However, there was little difference in meconium tobacco smoke metabolite concentrations 
among infants born to women with one or two serum measurements indicative of SHS exposure 
(Figure 3).  Infant meconium tobacco smoke metabolite concentrations were about 2 times 
higher in women with three serum measurements indicative of SHS compared to women with 
no tobacco smoke exposure.  Relative to differences in meconium NIC concentrations, 
meconium COT and 3HC concentrations were higher among active smokers and women with 
three serum measurements indicative of SHS exposure compared to women with no exposure. 
Secondhand or active tobacco exposures in later pregnancy resulted in greater 
increases in meconium NIC concentrations than exposures earlier in pregnancy (Figure 4).  
After adjustment for 26 week serum cotinine concentrations, meconium NIC concentrations 
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were higher among infants born to women with serum cotinine concentrations indicative of SHS 
exposure at birth only  (GM: 2.71; 95% CI: 1.65, 4.43) compared to infants born to women with 
serum cotinine concentrations indicative of SHS exposure at 16 weeks only (GM: 1.77; 95% CI: 
1.26, 2.48).     
A.3.2. Association between Biomarkers of Prenatal Tobacco Smoke Exposure and Infant 
Birth Weight 
 LOESS analysis revealed a linear relationship between serum and meconium tobacco 
smoke metabolite concentrations and infant birth weight.  Of the meconium tobacco smoke 
metabolites, NIC provided the largest and least precise point estimates compared to meconium 
COT and 3HC (Table 7).  Of the individual serum cotinine concentrations, birth serum cotinine 
categories of prenatal tobacco smoke exposure were the largest and most precise point 
estimates.  Meconium NIC concentrations provided estimates most similar to mean prenatal 
serum cotinine concentrations and birth serum cotinine concentrations.  Categorical meconium 
COT and 3HC estimates provided attenuated associations relative to birth and mean serum 
cotinine categories and meconium NIC categories. 
Estimates between SHS exposure and birth weight were similar when we evaluated  
different thresholds for classifying SHS and active exposure using meconium tobacco smoke 
metabolite concentrations.  However, raising the threshold for active exposure increased NIC 
point estimates between active smoking and birth weight and raising the threshold for COT and 
3HC decreased the point estimate between active smoking and birth weight. 
A.4. Discussion 
 Meconium tobacco smoke metabolites were positively associated with self-report and 
serum biomarkers of prenatal tobacco smoke exposure.  We observed a dose-dependent 
relationship between the number of serum cotinine measurements consistent with secondhand 
or active tobacco smoke exposure during the latter two-thirds of pregnancy and meconium 
tobacco smoke metabolite concentrations.  Our results indicate that tobacco smoke metabolites 
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in meconium reflect the duration and intensity, but not timing, of gestational exposure to tobacco 
smoke. 
Meconium COT and 3HC concentrations were higher and almost universally detected 
among infants born to active smokers compared to women with secondhand or no exposure.  
Meconium COT and 3HC concentrations may be a more sensitive biomarker of active prenatal 
tobacco smoke exposures, while meconium NIC concentrations may be a more sensitive 
marker of secondhand exposures since they were detected more frequently among infants with 
secondhand or no tobacco smoke exposure.  An additional advantage to meconium NIC is the 
higher frequency of detection reduces the need to impute left-censored data.142 
Meconium may be a more sensitive matrix to measure prenatal tobacco smoke 
exposure than serum if it reflects transient exposures that may not be captured by individual or 
serial serum measurements.  However, non-detectable serum cotinine concentrations could be 
due to increased nicotine and cotinine metabolism and clearance during pregnancy.140, 147  
Thus, women with tobacco smoke exposures that are not detectable using serum cotinine might 
give birth to infants with detectable meconium tobacco smoke metabolites.  We were not able to 
examine this hypothesis since we did not collect information about metabolic or genetic factors, 
like CYP2A6 enzyme activity, which may modify the relationship between tobacco smoke 
exposures and meconium tobacco smoke metabolites.148, 149  
 We detected a higher proportion of some meconium tobacco smoke metabolites than 
some previous studies.27, 139  Our proportion of detectable meconium COT and 3HC was similar 
to Gray et al..28  Another study reported almost universal meconium COT detection among their 
study participants.26  Variations in study results could be due differences in meconium 
digestion/extraction or analytical chemistry methods. 
Tobacco smoke exposures in later pregnancy may cause greater increases in meconium 
tobacco smoke metabolite concentrations relative to earlier exposures.  This complicates the 
interpretation of meconium metabolite concentrations since they reflect the duration, intensity, 
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and timing of exposure.  Differential accumulation of tobacco smoke metabolites in meconium 
over the course of pregnancy may be due to changes in blood volume, kidney and liver 
metabolism, placental perfusion, or increased quantities of amniotic fluid ingested by the infant 
later in gestation.150  However, inferences regarding the timing of tobacco smoke exposures are 
based on a relatively small number of women and infants with different temporal patterns of 
exposure.   
We are not aware of previous studies that attempted to validate meconium as a 
biomarker of prenatal tobacco smoke exposure using repeated serum cotinine measures for 
comparison.  Ostrea et al. reported meconium nicotine concentrations increased with self-
reported prenatal tobacco smoke exposure intensity.25  Kohler et al. reported higher meconium 
NIC, COT, and 3HC concentrations among women with greater duration of active smoking 
during pregnancy compared to women who quit smoking earlier in pregnancy, but these results 
were based on only eleven women who quit smoking during pregnancy.27  We were able to use 
serial serum measurements of prenatal exposure to accurately characterize exposure over the 
latter two-thirds of pregnancy. 
Both serum cotinine and meconium tobacco smoke metabolite concentrations were 
inversely associated with birth weight.  The magnitude and precision of the point estimates 
using meconium NIC concentrations was similar to serum cotinine concentration estimates 
within our cohort and to previous estimates of the association between prenatal serum cotinine 
concentrations and infant birth weight.5, 6, 102, 108, 143  Categorical meconium COT and 3HC point 
estimates were smaller in magnitude relative to categorical meconium NIC and serum cotinine 
point estimates; however, point estimates using continuous meconium tobacco smoke 
metabolite or serum cotinine concentrations were very similar to one another.  Investigators may 
wish to use serum cotinine measurements to quantify prenatal exposure since collecting and 
analyzing meconium samples will require additional resources.   
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There are some limitations to the presented results.  First, we considered mean prenatal 
serum cotinine concentrations as the gold standard for prenatal tobacco smoke exposure in 
these analyses.  Serum cotinine concentrations are a reasonable choice to compare a new 
biomarker of tobacco smoke exposure against since they are a more sensitive marker of 
secondhand exposure than self-report during pregnancy.9, 23, 41  However, it would have been 
ideal to compare meconium to another long term biomarker of prenatal tobacco smoke 
exposure like hair nicotine or cotinine.  
The small number of actively smoking women in our sample limited our ability to 
precisely estimate associations among active smokers.  However, among the larger number of 
women with SHS exposure, we did observe similar patterns of association between the number 
serum cotinine measurements indicative of SHS exposure and meconium tobacco smoke 
metabolite concentrations.    
 Finally, women in our sample were from relatively high socioeconomic background, 
which is associated with decreased active and SHS exposure during pregnancy.9, 23, 151  Thus, 
our results may not be generalizable to samples from populations with lower socioeconomic 
status who may have different exposure distributions. 
 There are several advantages and disadvantages to using meconium as a matrix to 
measure prenatal tobacco smoke exposure in epidemiological studies.  First, meconium 
tobacco smoke metabolite concentrations reflect the duration and intensity of prenatal 
exposures, providing an accurate estimate of the dose of tobacco smoke constituents received 
by the infant in the latter part of pregnancy.  In addition, meconium may be a good matrix to 
measure transient prenatal tobacco smoke exposures, as we detected nicotine in the meconium 
of infants born to women with undetectable serum cotinine concentrations and single serum 
cotinine measurement indicative of secondhand or active tobacco smoke exposure.  However, 
meconium tobacco smoke metabolite concentrations do not allow classification of exposure 
during specific time periods of development.  Furthermore, elevated meconium tobacco smoke 
 48
metabolite concentrations may be due to constant exposure over the entire course of pregnancy 
or high exposure in the latter parts of pregnancy.  Second, meconium could be used as a matrix 
for biomarkers of exposure in research studies that enroll women at or shortly after parturition, 
but does require additional resources to collect and analyze.  While both serum and meconium 
biomarkers provided similar estimates of association with birth weight, investigators should 
consider the additional resources necessary to collect and analyze meconium samples, 
especially if there are other well-developed biomarkers of exposure.   Meconium digestion and 
analysis, done at the CDC laboratory, was more labor intensive and less efficient than serum 
cotinine assays, taking approximately 4 times as long to complete.  
Meconium is a promising biological matrix to measure the duration and intensity of 
gestational exposure to environmental toxicants.  Investigators planning to use meconium 
should consider whether meconium toxicant concentrations will provide additional exposure 
information not gleaned from other well-developed biomarkers of exposure.  For studies of 
prenatal tobacco smoke exposure, meconium tobacco smoke metabolites do not provide 
additional exposure information that could not be captured by a single serum cotinine 
measurement.  Additional research should determine meconium’s ability to measure gestational 
exposure to other environmental toxicants.  In addition, future studies should compare 
meconium and other validated biomarkers of exposure with infant or child health outcomes in 
well characterized exposure-outcome relations. 
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Table 5: Distribution of demographic variables among mothers/infants in HOME study 
Variable All Women  
N =389 (%) 
Women with All 
Data N=315 (%) * 
Women Missing 
Any Data N=74 (%) 
  Maternal Race    
     White 237 (61.7) 209 (66.4) 28 (40.6) 
     Black 121 (31.5) 86 (27.3) 35 (50.7) 
     Other 26 (6.8) 20 (6.3) 6 (8.7) 
     Missing 5 0 5 
  Maternal Education (years)    
     <12 41 (10.7) 23 (7.3) 18 (26.1) 
     12 54 (13.8) 41 (13.0) 13 (18.8) 
     >12 289 (74.5) 251 (79.7) 38 (55.1) 
     Missing 5 0 5 
  Marital Status    
     Married 249 (64.8) 217 (68.9) 31 (44.9) 
     Single 135 (35.2) 98 (31.1) 38 (55.1) 
     Missing 5 0 5 
  Maternal Age Category 
(years) 
   
    <25 96 (24.7) 63 (20.0) 33 (44.6) 
    25-34 231 (59.4) 197 (62.5) 34 (45.9) 
    35+ 62 (15.9) 55 (17.5) 7 (9.5) 
    Missing 0 0 0 
*Women had all 3 serum cotinine measurements, both self-reported tobacco smoke interviews, 
meconium measurement, and infant birth outcome data. 
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Table 6: Geometric mean infant meconium tobacco smoke metabolite concentration by prenatal 
tobacco smoke exposure. 
  Meconium NIC Meconium COT Meconium 3HC 
 N  % 
Detect 
GM 
(95% CI) 
% 
Detect 
GM 
(95% CI) 
% 
Detect 
GM 
(95% CI) 
By Self-Reported Exposure        
   Unexposed Both Periods 232 69.3 1.74 (1.50, 2.01) 60.3 0.10 (0.08, 0.12) 45.2 0.08 (0.06, 0.11) 
   SHS Exposure 1 Period 21 85.7 2.20 (1.35, 3.59) 95.2 0.27 (0.12, 0.62) 85.7 0.32 (0.13, 0.81) 
   SHS Exposure Both Periods 27 85.2 2.56 (1.67, 3.94) 77.8 0.20 (0.09, 0.40) 59.3 0.15 (0.07, 0.34) 
   Active Exposure 1 Period 15 86.7 4.34 (2.44, 7.73) 93.3 0.92 (0.35, 2.43) 86.7 0.91 (0.31, 2.68) 
   Active Exposure Both Periods 21 100 26.8 (16.6, 43.1) 100 15.9 (7.0, 36.2) 95.5 23.3 (9.5, 56.8) 
By Mean Serum Cotinine        
   Unexposed (<LOD) 131 70.6 1.50 (1.24, 1.82) 48.1 0.07 (0.05, 0.09) 33.8 0.05 (0.04, 0.07) 
   SHS Exposure (LOD – 3 ng/mL) 170 83.9 2.08 (1.76, 2.45) 79.4 0.16 (0.12, 0.21) 65.3 0.15 (0.12, 0.21) 
   Active Exposure (> 3 ng/mL) 37 94.7 21.3 (15.0, 30.1) 100 16.8 (9.7, 29.0) 97.4 21.3 (11.5, 39.3) 
By Cumulative Serum Cotinine        
  Unexposed all 3 Measures 61 71.2 1.32 (0.99, 1.76) 50 0.05 (0.03, 0.07) 30.0 0.03 (0.02, 0.05) 
  SHS Exposure in 1 Measure 61 65.5 1.57 (1.18, 2.10) 46.7 0.08 (0.05, 0.12) 40.0 0.07 (0.04, 0.11) 
  SHS Exposure in 2 Measures 41 71.8 1.70 (1.20, 2.42) 65 0.09 (0.05, 0.14) 40.0 0.07 (0.04, 0.12) 
  SHS Exposure in 3 Measures 92 89.2 2.41 (1.92, 3.03) 89.4 0.19 (0.14, 0.26) 72.5 0.18 (0.12, 0.27) 
  Active Exposure in 1 Measure 14 92.9 4.87 (2.71, 8.75) 100 2.77 (1.20, 6.37) 92.9 1.98 (0.75, 5.25) 
  Active Exposure in 2 Measures 3 100 24.6 (6.92, 87.3) 100 13.3 (2.20, 80.5) 100 20.6 (2.50, 170) 
  Active Exposure in 3 Measures 22 95.6 27.6 (17.5, 43.7) 100 20.6 (10.6, 40.0) 100 32.3 (15.1, 69.3) 
*-Indicates any detectable meconium tobacco smoke metabolite.   
**-Concentration in ng/gm 
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Table 7: Adjusted association between log10-transformed serum and meconium 
biomarkers of tobacco smoke exposure and infant birth weight.*  
 N Change in Birth Weight 
(95% CI) 
Confidence Limit 
Difference†  
Meconium NIC    
  Unexposed (<LOD) 62 Ref --- 
  SHS (LOD – 10 ng/gm) 212 -136 (-295, 24) 320 
  Active (>10 ng/gm) 28 -135 (-395, 126) 520 
  Continuous† 302 -62 (-178, 53) 231 
Meconium COT    
  Unexposed (<LOD) 97 Ref --- 
  SHS (LOD – 5 ng/gm) 171 -27 (-175, 120) 295 
  Active (>5 ng/gm) 34 -106 (-348, 135) 482 
  Continuous† 302 -61 (-132, 10) 143 
Meconium 3HC    
  Unexposed (<LOD) 135 Ref --- 
  SHS (LOD – 10 ng/gm) 139 -100 (-246, 46) 292 
  Active (>10 ng/gm) 28 -57 (-307, 192) 500 
  Continuous† 302 -30 (-96, 36) 132 
Mean Serum COT    
  Unexposed (<LOD) 122 Reference --- 
  SHS (LOD to 3 ng/mL) 148 -112 (-264, 41) 305 
  Active (> 3 ng/mL) 32 -189 (-462, 84) 545 
  Continuous† 302 -60 (-135, 16) 150 
16 Week Serum COT     
  Unexposed (<LOD) 101 Reference --- 
  SHS (LOD to 3 ng/mL) 162 -20 (-173, 132) 305 
  Active (> 3 ng/mL) 32 -109 (-386, 168) 554 
  Continuous† 295 -59 (-125, 7) 132 
26 Week Serum COT     
  Unexposed (<LOD) 126 Reference --- 
  SHS (LOD to 3 ng/mL) 138 20 (-135, 175) 305 
  Active (> 3 ng/mL) 29 -138 (-425, 150) 554 
  Continuous† 293 -41 (-104, 21) 125 
Birth Serum COT     
  Unexposed (<LOD) 121 Reference --- 
  SHS (LOD to 3 ng/mL) 131 -97 (-248, 54) 302 
  Active (> 3 ng/mL) 29 -190 (-462, 82) 545 
  Continuous† 281 -40 (-104, 24) 128 
*-Adjusted for maternal age (18 to <25, 25 to <35, and 35+ years), race (non-Hispanic white, non-
Hispanic black, and other), education (<12, 12, and >12 years), martial status (married and unmarried), 
depression (minimal, mild, and moderate/severe), parity (0, 1, and >1) and maternal weight (in weight 
models)/height (in length models).   
†-Calculated by subtracting the lower 95% confidence limit from the upper 95% confidence limit 
‡-Coefficients represent change in weight, length, head circumference, and gestational age for a  
10-fold increase in metabolite concentration
 52
 Figure 3: Geometric mean meconium tobacco smoke metabolite concentration by duration and 
intensity of prenatal tobacco smoke exposure. 
 
 
 
 
 
 
 
 
Figure 4: Adjusted* geometric mean meconium nicotine concentration by 16 week and birth 
serum cotinine category 
 
*-Adjusted for 26 weeks serum cotinine category (<LOD, LOD – 3ng/mL, and > 3ng/mL) 
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B. Manuscript 2: Prenatal Tobacco Smoke Exposure and Early Childhood BMI 
B.1. Introduction 
 Between 15 and 20% of United States children have overweight body mass index (BMI) 
and the proportion of children with overweight BMI is increasing in other countries.152, 153  
Elevated childhood BMI is associated with increased BMI and adiposity in adolescence and 
adulthood.154, 155   Increased childhood BMI may also be a risk factor for metabolic disorders in 
early adulthood and coronary heart disease in later adulthood.156, 157     
 Several studies have observed excess adiposity and increased risk of overweight or 
obese BMI among children born to women who actively smoke during pregnancy compared to 
children born to non-smokers.19, 21, 22, 158  A recent meta-analysis of 14 studies indicates that 
children born to active smokers have 1.5-times the risk of overweight or obesity as children born 
to non-smokers.18  Increases in BMI and adiposity among children born to active smokers may 
be due to decreased weight and length at birth, rapid weight gain after birth, and decrements in 
height during childhood.10, 15, 19, 82, 83, 159, 160   
 Less is known about the association between prenatal SHS exposure and childhood 
BMI.  We are aware of only two studies examining the association between prenatal 
secondhand tobacco smoke exposure and childhood BMI.  Leary et al. reported elevated BMI, 
total body fat, and truncal fat among 10-year old children whose mothers had a partner who 
smoked during pregnancy.21  Oken et al. did not report any association between self-reported 
prenatal secondhand tobacco smoke exposure and BMI at 3 years of age.22   
Prior studies examining the association between prenatal active and secondhand 
tobacco smoke exposure and childhood BMI have relied on self-reported exposures.  Self-
reported secondhand tobacco smoke exposures may result in exposure misclassification that 
could bias the association between prenatal exposure and childhood BMI.9, 23, 33  A prospectively 
collected, valid biomarker of exposure might provide a more accurate estimate of the dose of 
tobacco smoke constituents received by the mother and fetus.   
 Given widespread exposure to secondhand tobacco smoke,161 especially in newly 
industrialized countries,13, 14 and the potential adverse health consequences of increased 
childhood BMI, we investigated the association between prenatal tobacco smoke exposure and 
early childhood BMI.   In addition, we estimated and compared the associations between self-
report and serum cotinine biomarkers of prenatal tobacco smoke exposure and early childhood 
BMI.   
B.2. Methods 
B.2.1 Study Sample 
 We used data collected from mothers and their children participating in the Health 
Outcomes and Measures of the Environment Study, an ongoing prospective birth cohort in the 
Cincinnati metropolitan area designed to examine low-level environmental toxicant exposure 
and the efficacy of injury and lead hazard controls in the home.162  Between March of 2003 and 
January of 2006, women were identified from seven prenatal clinics associated with three 
hospitals.  We mailed letters to 5,512 women > 18 years of age who were living in a home built 
before 1978 to see if they were eligible and interested in participating in our study.  Additional 
eligibility criteria included: < 19 weeks gestation upon enrollment; living in Brown, Butler, 
Clermont, Hamilton, or Warren counties in Ohio; intention to continue prenatal care and deliver 
at collaborating obstetric practices; HIV negative; and not receiving seizure, thyroid, or 
chemotherapy/radiation medications.  Of the 1,263 eligible women, 468 enrolled in our study.  
The current analyses were further restricted to singleton children.    
B.2.2 Tobacco Smoke Exposure 
 Women were interviewed twice about secondhand and active tobacco smoke exposures 
for the periods between conception and 20 weeks (measured at 20 week home visit) and 20 
weeks and birth (measured at 4 week postpartum visit) by trained research staff.  Trained 
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interviewers asked the women the average number of cigarettes they smoked per day (if any), 
the number of smokers living in the home, and the number of cigarettes smoked per day in the 
home for each time period.  Women were classified as unexposed if they reported no exposure 
for all of pregnancy.  Women with active exposure during one or both periods were classified as 
active smokers.  All others were classified as having SHS exposure. 
B.2.2.1 Self-Reported Exposure 
 Birth weight and length were abstracted from the child’s medical records.  Subsequent 
weight and height measurements were obtained by study staff in the child’s home or at our 
study clinic at 4 weeks and 1, 2, and 3 years of age.  Each measurement was taken three times 
and the mean was used in the analysis.  Weight was measured at 4 weeks and 1 year with an 
infant scale and at 2 and 3 years with a pediatric scale.  Length at 4 weeks and 1 year was 
taken using a length board.  At 2 and 3 years, height was obtained using a stadiometer; 
however, if the child was uncooperative at 2 years, I used a length board.129  BMI was 
calculated by dividing weight in kilograms by height in meters squared. 
B.2.2.2 Serum and Meconium Biomarkers of Exposure 
 Women provided blood samples around 16 weeks gestation, 26 weeks gestation, and 
within 24 hours of birth.  All samples were stored at -20o C until they were transported to the 
Centers for Disease Control and Prevention (CDC) laboratory for analysis, where they were 
stored at or below -20o C.  Serum from each sample was assayed for cotinine, a biomarker of 
nicotine exposure, using high performance liquid chromatography tandem mass spectroscopy 
(HPLC-MS/MS).42  The limit of detection (LOD) for this assay was 0.015 ng/mL.    
Prenatal serum cotinine concentrations were categorized as no exposure (<LOD), SHS 
exposure (LOD to 3 ng/mL), and active exposure (>3 ng/mL).  The threshold of 3 ng/mL for 
active smoking was chosen based on results from the 1999-2004 National Health and Nutrition 
Examination Survey using self-reported smoking status and serum cotinine levels among a 
representative sample of the US population.134  These results showed that using a higher 
cutpoint of 15 ng/mL as the threshold for active smoking underestimates the proportion of active 
smokers.  Prenatal serum cotinine concentrations were also analyzed as a continuous log10-
transformed variable.  In addition, we estimated the association between continuous prenatal 
serum cotinine concentrations and BMI among women with no prenatal active smoking (serum 
cotinine concentrations <3 ng/mL at each measurement).   
B.2.3 Infant and Childhood Growth 
B.2.3.1 Infant and Childhood Weight and Height Measurements 
 Birthweight and length were abstracted from the child’s medical records.  Subsequent 
weight and height measurements were obtained by study staff in the child’s home or at our 
study clinic at 4 weeks and 1, 2, and 3 years of age.  Each measurement was taken three times 
and the mean was used in the analysis.  Weight was measured at 4 weeks and 1 year with an 
infant scale and at 2 and 3 years with a pediatric scale.  Length at 4 weeks and 1 year was 
taken using a length board.  At 2 and 3 years, height was obtained using a stadiometer; 
however, if the child was uncooperative at 2 years, we used a length board.  BMI was calculated 
by dividing weight in kilograms by height in meters squared. 
 BMI was modeled as a continuous and dichotomous outcome.  BMI was dichotomized to 
classify children as overweight at 2 or 3 years of age.  We defined children as overweight if they 
had age and sex specific BMI > the 85th percentile at 2 or 3 years of age. 163 
B.2.4 Confounders 
 We used directed acyclic graphs (DAGs) to examine the role of confounding by 
sociodemographic, perinatal, and childhood nutrition factors in our exposure-outcome 
relation.145  Sociodemographic covariates were collected at the baseline clinic visit and included 
maternal age (<25, 25-34, and >35 years), race (non-Hispanic white, non-Hispanic black, and 
other), education (<12, 12, and >12 years), marital status (married and non-married), and 
household income (in increments of $10,000).  Perinatal variables were maternal depression, 
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maternal BMI at 16 weeks gestation, and parity.  Depression was measured at 20 weeks 
gestation with the Beck Depression Inventory (BDI-II).164  Women were classified as minimally 
depressed (BDI-II score <14), mildly depressed (BDI-II score 14-19), or moderately/severely 
depressed (BDI-II score >20).  Maternal BMI was modeled as a continuous variable from weight 
and height measurements collected at the 16-week prenatal clinic visit.  Parity was abstracted 
from medical records and coded as 0, 1, and >1.  Breastfeeding was collected quarterly during 
telephone interviews and included as a proxy of infant/childhood nutrition.  We modeled 
breastfeeding as a time-varying covariate coded as the length of time (in fractions of years) in 
which the child received any breast milk since the last study visit.  At birth, children were given a 
value of 0 years of breastfeeding.   
The HOME Inventory, a semi-structured interview that assesses the quality of the 
caregiving environment, was administered by trained interviewers during a home visit when the 
child was 1 year old.132  The HOME score, as a continuous variable, was evaluated as an 
additional proxy for socioeconomic status in a secondary analysis that examined the potential 
for residual confounding after controlling for household income and maternal education.  We did 
not adjust for gestational age at birth since our DAG placed it on a causal pathway between 
prenatal tobacco smoke exposure and childhood growth.   
B.2.5 Statistical Analysis 
 We descriptively compared the demographic characteristics of mothers and their 
children who had complete and missing covariate or exposure data.  We also calculated the 
Pearson correlation coefficients between log10-transformed prenatal serum cotinine 
concentrations at each pair of time points.    
We examined the shape of the relationship between continuous prenatal serum cotinine 
concentrations and children’s BMI at each measurement using Locally Weighted Scatter Plot 
Smoothing (LOESS) analysis.  LOESS uses locally weighted polynomials to fit subsets of data 
using ordinary least squares regression, giving more weight to points near the exposure value 
whose response is being estimated and less weight to points farther away.133 
 Since our data involved repeated measurements on individuals, we used linear mixed 
models to examine the association between prenatal tobacco smoke exposure and BMI over 
the first 3 years of life.165  Models were fit with time since birth (i.e., age in years), time-squared, 
and time-cubed terms.  We allowed the association between prenatal tobacco smoke exposure 
and childhood size to vary over time by including interaction terms between tobacco smoke 
exposure and time variables.  Tobacco smoke parameter estimates from our categorical models 
represent the mean change in BMI from the reference category, while estimates from models 
using continuous cotinine concentrations represent the mean change for each unit increase in 
log10-transformed (i.e., 10-fold increase) serum cotinine concentrations.  
 We used logistic regression with generalized estimating equations to estimate the 
association between secondhand and active prenatal tobacco smoke exposure and being 
overweight (BMI > 85th percentile) at 2 or 3 years of age.129  We generated odds ratios (OR) for 
being overweight given prenatal exposure to secondhand or active tobacco smoke compared to 
no exposure. 
B.2.6 Secondary Analyses 
We examined which component of BMI was responsible for associations between 
prenatal tobacco smoke exposure and BMI by constructing linear mixed models using 
categorical prenatal serum cotinine concentrations as the predictor variable and continuous 
weight or height z-scores at birth, 4 weeks, and 1, 2, and 3 years as the outcome.  We 
calculated weight and height z-scores using publicly available software from the National Center 
for Health Statistics.166  Our analyses were repeated using data from participants who had BMI 
measurements from all four visits to determine if children with incomplete data had excessive 
influence on our results.  Finally, we constructed linear mixed models to analyze the association 
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between individual serum cotinine concentrations (16 week, 26 week, and birth) and BMI over 
the first 3 years of life.   
B.2.7 Ethical Considerations 
 The Institutional Review Boards (IRB) of the University of North Carolina-Chapel Hill, 
Cincinnati Children’s Hospital Medical Center, and CDC approved this study.  The University Of 
Cincinnati College Of Medicine IRB was involved in the oversight of this study.  All mothers 
provided written informed consent for themselves and their children prior to enrollment in the 
study. 
B.3 Results 
 Of the 468 women who initially enrolled in our study, 67 dropped out before delivery.  
We excluded 9 non-singleton and 3 still-born children.  Of the remaining 389 women and 
infants, at least two prenatal serum cotinine samples were collected and assayed from 384 
(99%) women and self-reported prenatal tobacco smoke exposure was collected from 356 
(92%) women.  A higher proportion of women with complete self-report, serum cotinine, and 
covariate data at birth (N=292, 75%) were non-Hispanic white, better educated, wealthier, 
married, multiparous, and 25-34 years of age than women with missing data (Table 9).  Of 
these women and infants, 202 (52%) had complete covariate data and follow up data at 3 years 
of age.   
Nearly half of women (48%) with no self-report of prenatal tobacco smoke exposure had 
serum cotinine concentrations indicative of secondhand exposure (Table 10).  Almost 84% of 
women who self-reported active smoking had corresponding serum cotinine concentrations.  
Pairs of prenatal serum cotinine concentrations taken at different times during pregnancy were 
highly correlated (Pearson R=0.7-0.8).  
We observed an approximately linear relationship between log10-transformed prenatal 
serum cotinine concentration and weight, height, and BMI using LOESS analyses and 
characterized log10-transformed serum cotinine concentrations as continuous variables in 
subsequent analyses.  
After adjustment for confounders, children with prenatal active tobacco smoke exposure 
had higher mean BMI at 1, 2, and 3 years of age compared to unexposed children (Table 11).  
The pattern of association was similar using self-report or serum cotinine concentrations to 
classify exposure.  The mean difference in BMI between unexposed and actively exposed 
children increased from 1 to 3 years of age.  The HOME inventory score did not improve 
adjustment for socioeconomic confounding over maternal education and household income and 
was not retained in our models.     
 Children born to women self-reporting secondhand prenatal tobacco smoke exposure 
had BMI similar to unexposed children at all 5 measurements (Table 11).  However, children 
born to women with serum cotinine concentrations indicative of SHS exposure had similar BMI 
at birth, 4 weeks, and 1 year, but higher BMI at 2 and 3 year of age compared to unexposed 
children (Table 11).  
Children born to active smokers had increased odds of overweight BMI at 2 or 3 years of 
age compared to unexposed children (Table 12).  The magnitude of association was greater for 
serum cotinine, but less precise than that for the self-reported association.  Children with 
prenatal SHS exposure had increased odds for overweight BMI at 2 and 3 years of age when 
exposure was classified by serum cotinine concentrations, but not by self-report.   
B.3.1 Secondary Analyses 
 As expected, at birth children with prenatal secondhand and active tobacco smoke 
exposure had lower weight (Mean Difference [MD] SHS vs. unexposed: -112, 95% CI: -268, 33; 
MD active vs. unexposed: -136; 95% CI: -405, 132) and shorter length (MD SHS vs. unexposed: 
-0.8, 95% CI: -1.5, -0.1; MD active vs. unexposed: -1.2; 95% CI: -2.4, 0) than unexposed 
children.  Increased BMI at 2 and 3 years of age was the result of increased weight among 
prenatally exposed children at 2 and 3 years of age compared to unexposed children (Figure 
 
 
62
 
 
 
63
5).  In contrast, height at 1, 2, or 3 years of age was similar across categories of prenatal 
tobacco smoke exposure using self-report or serum cotinine concentrations (results for serum 
cotinine shown in Figure 1).   
Our associations between prenatal serum cotinine concentrations and early childhood 
BMI were strengthened when we restricted analyses to the 194 children who completed all 4 
follow-up visits.  For example, at 3 years of age children with prenatal secondhand [MD: 0.53; 
95% CI: 0.06, 1.00] and active [MD: 1.36; 95% CI: 0.47, 2.25] serum cotinine concentrations 
had higher BMI at 3 years compared to unexposed children.   
Results from models separately examining 16 week, 26 week, and birth serum cotinine 
concentrations in relation to BMI were relatively similar to results using mean prenatal serum 
cotinine concentrations.  Point estimates using individual or mean serum cotinine were similar in 
magnitude and precision for prenatal active tobacco smoke exposure.  The point estimates for 
SHS were somewhat higher from serum cotinine concentrations taken at 26 weeks and birth 
compared to 16 week serum concentration estimates, but similar to mean prenatal serum 
cotinine concentration estimates. 
B.4. Discussion 
Children with prenatal active tobacco smoke exposure, classified using self-report or 
serum cotinine concentrations, had higher BMI and odds of overweight BMI at 2 or 3 years of 
age compared to unexposed children.  Our results using serum cotinine concentrations were 
more suggestive of increased BMI among children with prenatal SHS exposure than the results 
using self-reported exposures.  Self-reported secondhand tobacco smoke exposures were 
misclassified to a greater extent than self-reported active smoking, and accordingly, the point 
estimates were attenuated when compared to estimates based on serum cotinine 
concentrations.   
Prior studies of prenatal tobacco smoke exposure and BMI have relied on self-reported 
tobacco smoke exposures and many studies have compared actively smoking women to non-
smokers, without considering the impact SHS exposure, which, if misclassified as unexposed, 
may have contributed to an underestimate the impact of active prenatal tobacco smoke 
exposure on childhood BMI.  Our results show that self-reported tobacco smoke measures fail 
to accurately quantify secondhand tobacco smoke exposures and may result in biased 
estimates of association.   
Several investigators have reported increased BMI and risk of overweight BMI among 2-
4 year old children born to active smokers.18, 19, 22, 158, 167  ORs between prenatal active smoking 
and overweight BMI in prior studies range from 1.2 to 2.2.19, 22, 158, 167  Our estimated association 
between active smoking and BMI were less precise than prior estimates, similar to Oken et al.  
and Adams et al. (OR: 2.2),22, 158 and larger than Chen et al. and Whitaker et al. (OR: 1.2-1.5).19, 
167  
 Consistent with our findings, Oken and colleagues did not report increased BMI among 3 
year old children born to women with self-reported prenatal secondhand tobacco smoke 
exposure.22  However, Leary et al. reported that 10 year old children born to women whose 
partners smoked regularly during pregnancy had BMI 0.1 standard deviations higher than 
unexposed children.21  The discrepancy in results could be due to differences in tobacco smoke 
exposure questionnaire, temporal or geographic variations in secondhand exposure, or age of 
follow-up.  
Increased weight at 2 or 3 years of age was responsible for increases in BMI among 
children born to women with serum cotinine concentrations consistent with secondhand and 
active tobacco smoke exposures.  Children with prenatal tobacco smoke exposures were born 
lighter and shorter and grew heavier over the first 3 years of life compared to unexposed 
children.  Attained height at 1, 2, or 3 years of age was similar between categories of prenatal 
tobacco smoke exposure.  
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Prenatal tobacco smoke exposure may influence childhood BMI by restricting fetal 
growth as a result of vascocontriction and hypoxemia.82, 159, 160, 168  Restricted fetal growth may 
lead to rapid weight gain, resulting in increased BMI and adiposity during early childhood.20, 160  
In addition, tobacco smoke constituents may act on various hormonal systems that change 
metabolic programming.169, 170  There has also been some suggestion that prenatal tobacco 
smoke exposure may alter infant appetite and leptin concentrations.115, 171, 172  
 The results of this study should be considered in light of several limitations.  
Confounding due to dietary, lifestyle, or socioeconomic factors may eliminate the observed 
elevation in BMI among children born to women with serum cotinine concentrations indicative of 
SHS exposure.  Women who smoke or are exposed to higher levels of SHS during pregnancy 
are less likely to provide optimal diets and exercise for their children.173, 174   Residual 
confounding may eliminate the positive association between prenatal secondhand tobacco 
smoke exposure and BMI at 2 and 3 years of age.  We attempted to indirectly control for 
confounding due to dietary or lifestyle factors by including breast feeding duration and maternal 
BMI in our models.  In addition, we controlled for other markers of socioeconomic status, 
including household income and maternal education which are associated with diet and 
exercise.175, 176  We also used HOME Inventory scores as a proxy for socioeconomic, dietary, 
and exercise factors not captured by other variables.  Our results were not substantially different 
when we included HOME Inventory scores in our models.  
While serum cotinine is considered an ideal biomarker for tobacco smoke exposure, it 
only reflects exposure over the last 2 to 3 days, which introduces the potential for exposure 
misclassification.30, 41  Women could have been exposed intermittently (e.g., only on weekends).  
However, we do not believe this is a substantial source of bias since serum cotinine 
concentrations were highly correlated and we used 2 or more prenatal serum samples from 
each woman to quantify prenatal exposure.   
 Increased BMI can result from increases in fat mass or fat-free mass.  Other measures 
of body composition, including densitometry, bioelectric impedance, dual energy x-ray 
absorptiometry (DXA), and isotope dilution can derive these separate components of body 
composition and provide more accurate quantification of excess adiposity.177  In addition, BMI is 
differentially correlated with direct measures of adiposity, with higher correlation among children 
> 85th BMI percentile.178  While there are limitations to using BMI as a marker of early childhood 
adiposity, BMI is endorsed by the World Health Organization to measure and track body 
composition across the life-course.179  Future research should examine the association between 
prenatal tobacco smoke exposures using direct measures of fat and fat-free mass and study 
children in later childhood when BMI measurements become more reflective of adult 
adiposity.155 
A substantial proportion of women and their children dropped out of the study by 3 years 
of age.  Attrition in our study was associated with socioeconomic factors, which are related to 
health and caregiving behaviors that influence childhood adiposity and tobacco smoke 
exposures.  The association between prenatal serum cotinine concentrations and BMI was 
slightly strengthened when we restricted to children who completed all four follow-up visits.    
Women in this study were required to be living in housing built before 1978.  We do not 
believe this limits the generalizability of our study, since almost 70% of US housing units were 
built prior to 1978.180   However, we analyzed a relatively homogenous sample of mothers who 
come from higher socioeconomic backgrounds which may reduce the generalizability of these 
results to samples drawn from populations with lower SES.   
These results suggest that prenatal serum cotinine concentrations may be associated 
with increased BMI and odds of overweight BMI at 2 and 3 years of age.  Given the high 
prevalence of tobacco smoke exposure and detrimental health consequences of increased BMI, 
additional research should be conducted examining the relationship between prenatal SHS 
exposures and childhood BMI and adiposity.  Specifically, future studies should use validated 
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biomarkers of tobacco smoke exposure to reduce misclassification of SHS exposure and 
examine this association at later ages.  The presented findings add to a growing body of 
literature suggesting that prenatal environmental insults-including secondhand tobacco smoke 
exposure- may impact the public’s health by influencing the risk of later life health outcomes 
through excess childhood BMI.181, 182 
Table 8: Distribution of demographic variables among mothers/infants in Health Outcomes and 
Measures of the Environment study 
Variable All Mothers and 
Infants  
N =389 (%) 
Mothers and Infants 
with Complete Data 
N=292 (%) 
Mothers and Infants 
with Missing Data 
N=97 (%) 
  Maternal Race    
     Non-Hispanic White 237 (61.7) 191 (65.4) 46 (50.0) 
     Non-Hispanic Black 121 (31.5) 84 (28.8) 37 (40.2) 
     Other 26 (6.8) 17 (5.8) 9 (9.8) 
     Missing 5 0 5 
  Maternal Education (years)    
     <12 41 (10.7) 27 (9.2) 14 (15.2) 
     12 54 (14.1) 36 (12.3) 18 (19.6) 
     >12 289 (75.3) 229 (78.4) 60 (65.2) 
     Missing 5 0 5 
  Marital Status    
     Married 249 (64.8) 197 (67.5) 52 (56.5) 
     Single 135 (35.2) 95 (32.5) 40 (43.5) 
     Missing 5 0 5 
  Maternal Age Category (years)    
    <25 96 (24.7) 60 (20.5) 35 (36.5) 
    25-34 231 (59.4) 181 (62.0) 50 (52.1) 
    35+ 62 (16.0) 51 (17.5) 11 (11.5) 
    Missing 0 0 0 
  BDI at 20 Weeks    
    Minimal Depression (0-13) 291 (7.6) 232 (79.4) 59 (71.1) 
    Mild Depression (14-19) 54 (24.4) 35 (12.0) 19 (22.9) 
    Moderate or Severe Depression (20-28) 30 (8.0) 25 (8.6) 5 (6.0) 
    Missing 14 0 14 
  Parity    
    0 171 (44.2) 122 (41.8) 49 (51.6) 
    1 124 (32.0) 91 (31.2) 33 (34.7) 
    >1 92 (23.8) 79 (27.0) 13 (13.7) 
    Missing 2 0 2 
  Prenatal Serum Cotinine Category    
    <LOD 140 (36.5) 114 (39.0) 26 (28.3) 
    LOD to 3 ng/mL 199 (51.8) 137 (50.4) 52 (56.5) 
    >3 ng/mL 45 (11.7) 31 (10.6) 14 (15.2) 
    Missing 5 0 5 
  Mean Maternal Weight at Baseline (SD) 75.0 (20.2) 74.8 (20.3) 75.7 (19.7) 
    Missing 5 0 5 
  Mean Maternal Height at Baseline (SD) 164.9 (6.8) 164.8 (6.7) 165.5 (7.2) 
    Missing 20 0 20 
  Mean BMI at Baseline (SD) 27.5 (6.8) 27.5 (6.9) 27.8 (6.4) 
    Missing 26 0 26 
  Mean Income in Thousands of Dollars (SD) 58 (43) 61 (43) 46 (41) 
    Missing 13 0 13 
  Mean Total Weeks of Breast Feeding (SD) 22.5 (23.4) 22.9 (23.3) 19.8 (24.3) 
    Missing 58 0 58 
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Table 9: Joint distribution of prenatal self-reported tobacco smoke exposure and serum cotinine 
concentration categories.   
 No Self-Reported 
Exposure N=214 
(%) 
Self-Reported 
Secondhand 
Exposure N=42 (%) 
Self-Reported 
Active Exposure 
N=36 (%) 
Unexposed (<LOD) 108 (50.5) 5 (11.9) 1 (2.8) 
SHS Exposure (LOD – 3ng/mL) 103 (48.1) 35 (83.3) 9 (25.0) 
Active Exposure (> 3ng/mL) 3 (1.4) 2 (4.8) 26 (72.2) 
Median Serum Cotinine 
Concentration (Min, Max) 
0.015 (<LOD, 14.9) 0.134 (<LOD, 3.92) 35.3 (<LOD, 355.5) 
*-Limited to women with complete covariate data.   
Table 10: Adjusted mean and difference in BMI by change in prenatal tobacco smoke 
exposure* 
Self-Reported Prenatal 
Tobacco Smoke Category 
N† Birth 
(N=293) 
4-Week (N=297) 1 Year (N=266) 2 Years 
(N=229) 
3 Years 
(N=202) 
Mean among Unexposed 214  13.5 (13.2, 13.7) 
14.0 
(13.7, 14.2) 
17.0 
(16.8, 17.2) 
16.7 
(16.4, 17.0) 
15.9 
(15.6, 16.2) 
SHS 43 0.0 (-0.4, 0.5) 
0.0 
(-0.4, 0.4) 
-0.1 
(-0.7, 0.4) 
-0.1 
(-0.6, 0.5) 
0.0 
(-0.5, 0.6) 
Active 36 0.3 (-0.2, 0.8) 
0.3 
(-0.2, 0.8) 
0.2 
(-0.4, 0.8) 
0.6 
(0.0, 1.2) 
1.1 
(0.4, 1.7) 
       
Categorical Prenatal Serum 
Cotinine Concentrations 
N† Birth 
(N=300) 
4-Week (N=303) 1 Year (N=273) 2 Years 
(N=236) 
3 Years 
(N=209) 
Mean among Unexposed 
(<0.015 ng/mL) 
116 13.4  
(13.1, 13.7) 
14.0 
(13.7, 14.3) 
17.3  
(16.9, 17.66) 
16.7 
(16.3, 17.1) 
15.8 
(15.4, 16.2) 
SHS (0.015-3 ng/mL) 153 -0.2 (-0.5, 0.2) 
-0.2 
(-0.5, 0.1) 
-0.1 
(-0.6, 0.3) 
0.3 
(-0.1, 0.7) 
0.4 
(0, 0.8) 
Active (>3 ng/mL) 31 0.0 (-0.6, 0.6) 
0.1 
(-0.5, 0.6) 
0.4 
(-0.4, 1.1) 
0.6 
(-0.1, 1.4) 
1.0 
(0.3, 1.8) 
Continuous Prenatal Serum 
Cotinine Concentrations 
      
  Log10-transformed mean    
  cotinine 
300 0.0 
(-0.2, 0.2) 
0.0 
(-0.2, 0.2) 
0.1 
(-0.1, 0.3) 
0.2 
(0.0, 0.4) 
0.3 
(0.1, 0.5) 
  Log10-transformed mean  
  cotinine  (Secondhand     
  exposed women) ‡ 
269 -0.1 
(-0.4, 0.2) 
-0.2 
(-0.5, 0.1) 
-0.2 
(-0.6, 0.2) 
0.2 
(-0.2, 0.5) 
0.3 
(-0.1, 0.6) 
*-Adjusted for child age (in years), child age squared, child age cubed, maternal age (<25, 25-34, and 
>34 years), education (<12, 12, and >12 years), race (non-Hispanic white, non-Hispanic black, and 
other), marital status (married and non-married), depression at baseline home visit (moderately or 
severely depressed and mildly or minimally depressed), breast feeding duration since last visit (years), 
parity (0, 1, and >1), income ($10,000 increments), and maternal BMI (kg/m2) at 16 weeks gestation. 
†-Sample size at birth 
‡-Women could not have cotinine concentration > 3 ng/mL in any serum measurement. 
SHS-Secondhand smoke 
§-Model with fit with birth, 4 week, and 1 year measurements.   
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Table 11: Unadjusted and adjusted association between categorical prenatal tobacco smoke 
exposure and overweight BMI at 2 or 3 years of age*  
 Total >85th   
Cases (%) 
>85th Unadjusted 
OR (95% CI) 
>85th Adjusted 
OR (95% CI) 
Self-Reported Prenatal 
Tobacco Smoke Category 
    
  Unexposed 307 43 (14.0) Reference Reference 
  SHS 56 9 (16.1) 1.2 (0.5, 3.1) 1.0 (0.3, 3.0) 
  Active 48 14 (29.2) 2.5 (1.0, 6.1) 1.9 (0.6,  6.1) 
Categorical Prenatal Serum 
Cotinine Concentrations 
    
  Unexposed (<0.015 ng/mL) 176 18 (10.2) Reference Reference 
  SHS (0.015-3 ng/mL) 209 40 (19.1) 2.1 (1.0, 4.5) 1.9 (0.8, 4.4) 
  Active (>3 ng/mL) 40 10 (25.0) 3.3 (1.1, 10.0) 2.4 (0.6, 9.7) 
*-Adjusted for maternal age (<25, 25-34, and >34 years), education (<12, 12, and >12 years), race (non-
Hispanic white, non-Hispanic black, and other), marital status (married and non-married), depression at 
baseline home visit (moderately or severely depressed and mildly or minimally depressed), breast feeding 
duration (years), parity (0, 1, and >1), income ($10,000 increments), and maternal BMI (kg/m2) at 16 
weeks gestation. 
 
Figure 5: Mean weight and height z-score from birth to 3 years of age by prenatal serum 
cotinine category.* † 
*-Adjusted for child age (in years), child age squared, child age cubed, maternal age (<25, 25-34, and 
>34 years), education (<12, 12, and >12 years), race (non-Hispanic white, non-Hispanic black, and 
other), marital status (married and non-married), depression at baseline home visit (moderately or 
severely depressed and mildly or minimally depressed), breast feeding duration since last visit (years), 
parity (0, 1, and >1), income ($10,000 increments), and maternal BMI at 16 weeks gestation. 
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CHAPTER 6: DISCUSSION 
A. Summary of Findings  
 The presented findings addressed two questions using prospectively collected data from 
approximately 350 mothers and their infants participating in the HOME Study.  First, are 
meconium tobacco smoke metabolite concentrations a useful biomarker of prenatal tobacco 
smoke exposure?  Second, are prenatal serum cotinine concentrations associated with 
childhood BMI over the first 3 years of life?   
 The results of the first aim show that meconium tobacco smoke metabolites reflect the 
duration and intensity of prenatal tobacco smoke exposure.  Infant meconium tobacco smoke 
metabolite concentrations were higher among women with self-reported and serum cotinine 
concentrations indicative of secondhand and active tobacco smoke exposure, in comparison to 
infant meconium metabolite concentrations among women unexposed to prenatal tobacco 
smoke.  There were not substantial differences in meconium tobacco smoke metabolite 
concentrations among infants born to women with 1 or 2 serum or self-reported measurements 
of SHS exposure.  This could be due to the poor sensitivity of self-report to capture secondhand 
exposures or little variability in meconium tobacco smoke metabolite concentrations among 
women with low-level SHS exposures.9, 23 
My results suggest that secondhand or active tobacco smoke exposures later in 
pregnancy may result in greater increases in meconium metabolite concentrations compared to 
earlier exposures.  Thus, elevated meconium tobacco smoke metabolite concentrations could 
be due to sustained exposure over the entire duration of pregnancy or high exposure near 
parturition.  This further complicates the cumulative nature of meconium as biological matrix of 
exposure since the rate of metabolite accumulation varies differentially across the course of 
pregnancy. 
Since meconium is biologically inert, it may be a sensitive matrix for detecting transient 
environmental exposures.  Two of my observations substantiate this.  First, 75% of women with 
mean serum cotinine concentrations below the LOD had at least one detectable meconium 
metabolite concentration.  Second, meconium metabolite concentrations were higher among 
infants born to women with only one serum cotinine concentration consistent with SHS 
exposure compared to women with all three serum cotinine concentrations below the LOD.   
Prior studies validating the utility of meconium have not had serial measures of prenatal 
tobacco smoke exposures.25, 27-29  Three studies have used maternal recall of prenatal tobacco 
smoke exposure25, 28, 29 and one used urinary cotinine concentrations at birth and self-report.27  
Meconium tobacco smoke metabolites were detected in a higher proportion of infants than prior 
studies, indicating that our NIC, COT, and 3HC assays are more sensitive than previously 
developed methods.  This is because our laboratory method was able to completely digest 
meconium into an aqueous solution. 
 I found that meconium tobacco smoke metabolites were inversely associated with infant 
birth weight, length, and head circumference.  Furthermore, meconium point estimates were 
similar in magnitude to mean prenatal serum cotinine concentration associations and to 
estimates from previous studies using serum cotinine as a biomarker of exposure.5, 6, 16, 102, 108, 
122  Prior studies have estimated that SHS exposure is associated with reductions in birth weight 
ranging from 10 to 150 grams.  A meta-analysis of 3 studies using serum cotinine levels 
estimated an 82 gram (95% CI: 37, 126) reduction in birth weight associated with prenatal 
SHS.5 
 In my second aim, I found that prenatal serum cotinine concentrations were associated 
with elevated BMI and odds of overweight BMI at 2 and 3 years of age.  Elevated BMI resulted 
from non-uniform increases in weight from birth to 3 years of age among children born to 
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women with serum cotinine concentrations indicative of secondhand and active tobacco smoke 
exposure (Appendix 1).  Prenatal active tobacco smoke exposures were associated with larger 
increases in BMI at 2 and 3 years of age compared to prenatal SHS.  Consistent with non-
differential exposure misclassification, the associations between self-reported SHS smoke 
exposure and BMI were attenuated towards the null compared to associations using serum 
cotinine concentrations to quantify SHS exposure. 
A meta-analysis of 14 studies found children born to smokers were 1.50-times (95% CI: 
1.36, 1.65) as likely to be obese or overweight as children born to non-smokers.18  My estimated 
association is 47% higher than the meta-analysis estimate.  The presented estimates were 
similar to two studies that have examined this association among 2-4 year old children (OR: 
2.2),22, 158 but larger than two other studies examining the same age children (OR: 1.2-1.5).19, 167  
However, the prior literature has not accounted for an association between prenatal 
secondhand tobacco smoke exposure and BMI, thus prior studies may have underestimated the 
association between active smoking and BMI.   
The two prior studies examining the association between prenatal SHS exposure and 
childhood BMI have reported different findings.  Oken et al. claimed no association between 
prenatal SHS exposure and BMI at 3 years of age.22  However, they did not provide point 
estimates or confidence intervals in their paper.  They appear to base their conclusion of no 
association based on non-significant p-values.  Consistent with my results,  Leary et al. reported 
that children born to women reporting prenatal SHS exposures had BMI 0.4 units higher than 
unexposed children at 10 years of age.21  This prior estimate may actually be larger if self-
reported SHS exposures were non-differentially misclassified in their study.      
My results suggest that increases in childhood BMI associated with prenatal tobacco 
smoke exposures are due to changes in early childhood weight trajectories.  Exposed children 
were born lighter and shorter and grew heavier over the first 3 years of life compared to 
unexposed children.  A prior study examining patterns of childhood growth over the first 8 years 
of life observed a similar phenomenon of increasing weight and decreased height among 
children born to smokers compared to children of non-smokers.19  Tobacco smoke constituents 
may act on a variety of biological pathways to influence childhood growth.  For example, 
nicotine may act as an appetite suppressant in utero and once removed after birth the infant 
may demand additional feeding.183   
B. Strengths and Limitations 
There presented results have strengths and limitations that should be considered when 
interpreting these results.  While my first aim was relatively straightforward, there are concerns 
about generalizability, validity of biomarkers, and confounding.   
Women and infants who had all self-report and biomarkers of prenatal tobacco smoke 
exposure were more likely to be higher SES than women with incomplete data.  In addition, 
women in my sample were better educated and wealthier than the source population.  Lower 
SES is associated with increased active and secondhand tobacco smoke exposure.9, 23, 43, 184  
These two biases limit the generalizability of my results to populations of women with lower 
socioeconomic backgrounds and greater prenatal tobacco smoke exposure.  However, these 
biases should not affect my internal validity.   
Picking a gold standard is a problem in any biomarker validation study and the choice of 
standard depends on the target tissue of interest (fetal or maternal) and timing and duration of 
exposure.  In Aim 1, I assumed that maternal serum cotinine concentrations, which reflect 
recent tobacco smoke exposure, were the gold standard.  This may not be appropriate since 
meconium reflects fetal exposure during the latter two-thirds of gestation.  Maternal hair nicotine 
or cotinine concentrations may serve as a better gold standard for comparison to meconium 
tobacco smoke metabolite concentrations.185  Given the low sensitivity of self-reported 
exposures9, 23 and lack of hair cotinine concentrations in this study, serum cotinine 
concentrations were the most sensible gold standard. 
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While I had two different measures of prenatal tobacco smoke exposures, each measure 
has strengths and limitations.  Self-reported measures of tobacco smoke exposures can be 
used to quantify exposure over longer periods of time; however, self-reported measures are 
known to misclassify women’s secondhand exposure.9, 23, 33, 39, 41  Unlike self-reported exposure, 
short-term markers like serum cotinine only reflect the last 2-3 days of exposure.41  Thus, a 
woman with exposure on weekends (e.g., at bars or restaurants), may be misclassified 
depending on the timing of her serum measurement.  Single serum measurements may be 
sufficient for classifying active smoking during pregnancy since active smoking tends to be 
relatively constant.186, 187  However, repeated measurements may be necessary to accurately 
characterize SHS exposures since women may try to reduce their exposure after learning they 
are pregnant.  Finally, pregnant women have increased CYP2A6 activity and kidney function 
resulting in increased NIC, COT, and 3HC metabolism.  Thus, tobacco smoke exposures that 
would produce detectable serum cotinine concentrations in non-pregnant women may produce 
non-detectable concentrations in pregnant women.147 
Residual confounding due to SES, dietary, or lifestyle factors may attenuate the 
association between serum and meconium metabolite concentrations and infant birth size and 
gestational age.  However, the magnitude of attenuation was similar for both meconium and 
serum measures.  Previous studies have observed an inverse association between prenatal 
serum cotinine concentrations and birth size even after adjustment for numerous perinatal and 
socioeconomic variables.5, 11 
There were similar limitations in Aim 2 regarding exposure assessment, but most 
important were the role of selection bias, residual confounding, and the use of BMI as a 
measure of adiposity.  Selection bias strengthened the association between prenatal tobacco 
smoke exposure and BMI at 3 years of age.  I believe this is due to higher in birth weight and 
length among infant with complete follow-up.  The association between prenatal tobacco smoke 
exposure and birth weight and length was attenuated among infants with complete follow-up; 
whereas, infants with incomplete follow-up had greater decrements in weight and length 
associated with prenatal tobacco smoke exposure.  The greater decrements in birth weight 
resulted in infants with incomplete follow-up having to catch up greater amounts of weight over 
the first 3 years of life as their similarly exposed peers to reach the same BMI.  If women and 
children with incomplete follow-up are truly biasing my estimates, then the presented results in 
Appendix 2 may be closer to the true association.   
My observed estimates may be biased away from the null due to residual confounding 
from dietary and lifestyle factors.  Prenatal tobacco smoke exposure is associated with lower 
SES, poor childhood diet, and less childhood activity.9, 23, 43, 175, 176, 184, 188  I used HOME scores 
as a proxy of childhood diet and exercise.  Additional adjustment for HOME scores did not 
substantially alter my results; however, the HOME scale may be an inappropriate proxy of 
dietary and exercise factors since it was originally designed to capture caregiving behaviors 
related to childhood neurodevelopment.131, 189, 190  Prior studies examining the association 
between prenatal active tobacco smoke exposure and overweight BMI have observed little 
attenuation of their estimates after adjustment for children’s diet or activity.18   
 Finally, I used BMI as an indirect measurement of adiposity.  While cross-sectional 
measures of BMI and skin fold thickness are highly correlated,127 elevated BMI can be a result 
of increased weight or decreased height.  In addition, increased weight can be driven by gains 
in fat-free or fat mass.  The correlation between BMI and fat mass is higher among overweight 
children compared to the correlation among normal weight children.178   I did not have additional 
anthropometric measurements that would have allowed me examine what which one of these 
factors was responsible for the increase in weight among exposed children.  However, I was 
able to utilize repeated measurements of weight and height to examine trajectories of early 
childhood growth. 
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C. Research and Public Health Implications 
Interest and enthusiasm in using meconium as a biological matrix to measure  
gestational exposure to environmental toxicants has prompted the National Children’s Study 
(NCS) to collect meconium from participating infants to quantify prenatal tobacco smoke and 
pesticide exposure.24, 136, 137, 191  Bearer recommended that several steps be taken to enhance 
the usability of meconium in the NCS and other studies: 1) develop high-throughput 
methodology to measure a wide variety of environmental toxicants in meconium, 2) determine 
the relationship between maternal exposure and meconium metabolite concentrations of 
expsoure, and 3) estimate the relationship between meconium toxicant concentrations and 
infant birth weight and compare them to the association with other established biomarkers of 
that exposure.  My first aim used prenatal tobacco smoke exposure as a system to complete 
these recommendations. 
Dr. Bernert and his staff developed a high throughput assay that was able to detect NIC, 
COT, and 3HC in meconium.  There were substantial hurdles in accomplishing this since 
meconium is a very difficult matrix to work with.  Much effort was devoted to finding a way to 
liquefy the meconium without degrading tobacco smoke metabolites.  Once dissolved into a 
liquid, the quantification of NIC, COT, and 3HC was relatively easy since they have very similar 
chemical structures.  However, the quantification of other classes of environmental toxicants 
(e.g. phthalates or pesticides) in meconium may be more difficult since these compounds may 
have larger variations in chemical structure, each of which may require different analytical 
chemistry techniques.   
Meconium NIC, COT, and 3HC concentrations can be used to approximate cumulative 
gestational tobacco smoke exposure.  In addition, meconium metabolite concentrations were 
inversely associated with infant birth size and these associations were similar to serum cotinine 
estimates.  
Epidemiologists considering meconium as a biological matrix to measure gestational 
toxicant exposure should ponder several factors.  First, meconium is easy to collect and does 
not require additional storage or shipping requirements compared to other biomarkers.  In 
addition, meconium could be collected in studies that enroll women at delivery, thus eliminating 
the need to enroll women and gather biomarkers throughout pregnancy.  However, collection of 
meconium samples may require additional cooperation from infant nursery staff to ensure that 
samples are not thrown away.  Second, a meconium assay for the chemical of interest could 
take a substantial amount of time to develop and may turn out to be less accurate, precise, or 
sensitive than other well-established assays.  In addition, quantification of tobacco smoke 
metabolites in meconium samples takes much longer serum samples.  Third, in the case of 
tobacco smoke, meconium NIC appears to be a sensitive marker of tobacco smoke exposure in 
the 2nd and 3rd trimester of pregnancy.  Meconium may be preferred in studies examining 
exposures with a high degree of temporal variability since meconium may capture exposures 
that serum or urine measurements would otherwise miss.  However, using meconium to 
quantify prenatal exposure may result in exposure misclassification in studies of outcomes with 
time-sensitive windows of development since meconium reflects the duration and intensity of 
exposure.  Fourth, the utility of meconium in a study depends on the exposure distribution of the 
source population.  A sensitive biomarker like meconium may be unnecessary if the source 
population has relatively high exposure, especially if there are existing sensitive and well-
developed assays.  Finally, future studies would be advised to use meconium NIC because of 
the large proportion of infants with non-detectable COT and 3HC concentrations.  This would 
make statistical analysis easier since biomarkers with a higher proportion of non-detectable 
values require more sophisticated techniques to handle left-censored data.142, 192 
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While meconium is a promising matrix to measure toxicant exposure, it is not necessary 
for most studies examining prenatal tobacco smoke exposure and infant or childhood health 
outcomes.  Given the additional challenges of collecting, processing, and analyzing meconium, 
a single serum cotinine measurement collected during pregnancy or at birth would be sufficient 
to quantify prenatal exposure for most studies.  However, meconium has the potential to be a 
useful biological matrix to measure environmental toxicants with a high degree of temporal or 
within-woman variability, including alcohol, pesticides, and phthalates.  Future studies should 
determine if these chemicals can be quantified in meconium and whether meconium is able to 
capture exposures that were missed by urine, serum, or self-reported measurements of 
exposure.    
Given the high prevalence of secondhand tobacco smoke exposures across the globe 
and the potentially devastating consequences of obesity, additional research examining the 
association between prenatal SHS and childhood BMI and adiposity is needed.  The findings of 
this dissertation underscore the importance of using validated biomarkers of tobacco smoke 
exposure in future studies given the potential for self-reported prenatal SHS exposures to be 
misclassified. 
The presented research confirms that prenatal secondhand and active tobacco smoke 
exposure is associated with decreased birth weight and length and suggests that secondhand 
tobacco smoke exposure may be associated with increased adiposity in children.  A growing 
body of literature suggests that early alterations in early childhood growth lead to increased, 
adiposity, early adulthood cardiovascular disease markers, and adult cardiovascular morbidity 
and mortality.77, 156, 193  Gestational exposures, like tobacco smoke, may increase disease risk in 
later life by decreasing birth weight and causing exposed children to undergo a period of rapid 
catch-up growth. 
 
D. Conclusions 
 These results show that meconium is a promising biological matrix to measure 
gestational exposure to environmental toxicants.  However, the utility of meconium in studies 
examining prenatal tobacco smoke exposure is questionable.  While meconium NIC, COT, and 
3HC metabolites are sensitive biomarkers of tobacco smoke exposure and highly correlated 
with prenatal serum cotinine concentrations, they provide similar associations with infant size 
and gestational age as serum cotinine associations.  Meconium tobacco smoke metabolites do 
not provide additional information that could be obtained from a single serum cotinine 
measurement at birth. 
 The findings in Aim 2 add to a growing body of literature suggesting that prenatal 
tobacco smoke exposures may be associated with later life obesity.  While additional research 
is needed to validate the presented findings; active and secondhand tobacco smoke exposures 
have been extensively studied and are causally linked to a variety of adverse infant, child, and 
adult health outcomes.10, 11  Newly industrialized countries, like China and India, that have a 
high prevalence of active and secondhand tobacco smoke exposures,12, 13 could learn from the 
successes and failures of tobacco regulation in Europe and North America.  Both newly 
industrialized and developed nations should reduce exposures to active and secondhand 
tobacco smoke by banning smoking in workplaces and public, reducing the initiation of smoking, 
and providing cessation services to active smokers.  Failure to take timely and nationally 
coordinated action may result in substantial morbidity and mortality among large portions of the 
population who are unwillingly exposed to tobacco smoke.   
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APPENDIX A 
 
A. Association between Prenatal Serum Cotinine Concentrations and Z-Scores of Weight, 
Height, and Weight-for-Height 
Adjusted weight, height, and weight-for-height z-scores were calculated using a publicly 
available SAS program.129  I observed a similar pattern of association (Table A1) between 
prenatal serum cotinine categories and z-scores as those presented above, with the exception 
of the association between prenatal active tobacco smoke exposure and weight-for-height z-
scores.  Children with prenatal active exposure had increased weight-for-height z-scores 0.2 to 
0.5 units higher at all five measurement occasions from birth to 3 years of age.   
 Mean z-scores were calculated at birth and 1, 2, and 3 years of age by prenatal tobacco 
smoke exposure category (Figure A1).  Children with prenatal secondhand or active tobacco 
smoke exposure were lighter and shorter at birth than unexposed children.  Weight increased 
among both groups of exposed children, but the magnitude of increase was less among children 
with prenatal SHS exposure.  Mean height z-scores remained unchanged between exposure 
groups across the first 3 years of life.  By age 3, children with active prenatal tobacco smoke 
exposure had weight-for-height z-scores 0.5 standard deviations (95% CI: 0.0, 1.0) higher than 
unexposed children. 
These results substantiate my previous findings using untransformed weight and height 
values.  In addition, they provide evidence that active and secondhand prenatal tobacco smoke 
exposures may alter early childhood weight trajectories, resulting in increased BMI (or weight-
for-height) by 3 years of age.   
 Table A1: Adjusted mean difference in weight, height, and weight-for-height z-scores by change in mean prenatal serum cotinine 
concentrations * 
 N (%)† Birth (N=300) 
4-Week 
(N=303) 
1 Year 
(N=273) 
2 Years 
(N=236) 
3 Years 
(N=209) 
Weight Z-Score Models       
Categorical Prenatal Serum Cotinine 
Concentrations 
 
 
 
   
  Unexposed (<0.015 ng/mL) 116 (38.8) Ref Ref Ref Ref Ref 
  SHS (0.015-3 ng/mL) 152 (50.8) -0.2 (-0.5, 0.0) -0.2 (-0.5, 0.1) 0.0 (-0.3, 0.3) 0.2 (-0.1, 0.5) 0.2 (-0.1, 0.5) 
  Active (>3 ng/mL) 31 (10.4) -0.3 (-0.8, 0.2) -0.2 (-0.7, 0.2) 0.3 (-0.2, 0.9) 0.3 (-0.3, 0.9) 0.4 (-0.2, 0.9) 
Continuous Prenatal Serum Cotinine 
Concentrations       
  Log10-transformed mean    
  cotinine 299 -0.1 (-0.2, 0.0) -0.1 (-0.2, 0.0) 0.0 (-0.1, 0.2) 0.1 (-0.1, 0.2) 0.1 (-0.1, 0.2) 
Height Z-Score Models       
Categorical Prenatal Serum Cotinine 
Concentrations 
 
 
 
   
  Unexposed (<0.015 ng/mL) 116 (38.8) Ref Ref Ref Ref Ref 
  SHS (0.015-3 ng/mL) 152 (50.8) -0.3 (-0.6, -0.1) -0.3 (-0.5, 0.0) 0.1 (-0.2, 0.4) 0.0 (-0.3, 0.3) 0.0 (-0.3, 0.3) 
  Active (>3 ng/mL) 31 (10.4) -0.5 (-0.9, 0.0) -0.4 (-0.8, 0.1) 0.2 (-0.3, 0.7) 0.1 (-0.4, 0.6) -0.1 (-0.6, 0.5) 
Continuous Prenatal Serum Cotinine 
Concentrations       
  Log10-transformed mean    
  cotinine 299 -0.1 (-0.3, 0.0) -0.1 (-0.2, 0.0) 0.0 (-0.1, 0.2) 0.0 (-0.1, 0.1) 0.0 (-0.2, 0.1) 
Weight-for-Height  Z-Score Models       
Categorical Prenatal Serum Cotinine 
Concentrations 
 
 
 
   
  Unexposed (<0.015 ng/mL) 116 (38.8) Ref Ref Ref Ref Ref 
  SHS (0.015-3 ng/mL) 152 (50.8) 0.1 (-0.2, 0.3) 0.0 (-0.2, 0.2) -0.1 (-0.4, 0.1) 0.1 (-0.2, 0.4) 0.2 (-0.1, 0.5) 
  Active (>3 ng/mL) 31 (10.4) 0.4 (0.0, 0.8) 0.4 (0.0, 0.8) 0.2 (-0.3, 0.7) 0.3 (-0.2, 0.8) 0.5 (0.0, 1.0) 
Continuous Prenatal Serum Cotinine 
Concentrations       
  Log10-transformed mean    
  cotinine 299 0.1 (0.0, 0.2) 0.1 (0.0, 0.2) 0.0 (-0.1, 0.1) 0.1 (-0.1, 0.2) 0.1 (0.0, 0.3) 
*-Adjusted for maternal age (<25, 25-34, and >34 years), education (<12, 12, and >12 years), race (non-Hispanic white, non-Hispanic 
black, and other), marital status (married and non-married), depression at baseline home visit (moderately or severely depressed and 
mildly or minimally depressed), breast feeding duration since last visit (years), parity (0, 1, and >1), income ($10,000 increments), and 
maternal BMI (kg/m2) at 16 weeks gestation. 
†-Sample size at birth
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 Figure A1: Adjusted Weight, Height, and Weight-for-Height Z-Scores from Birth to Three 
Years of Age by Prenatal Tobacco Smoke Exposure. 
 
*-Adjusted for maternal age (<25, 25-34, and >34 years), education (<12, 12, and >12 years), 
race (non-Hispanic white, non-Hispanic black, and other), marital status (married and non-
married), depression at baseline home visit (moderately or severely depressed and mildly or 
minimally depressed), breast feeding duration since last visit (years), parity (0, 1, and >1), 
income ($10,000 increments), and maternal weight(kg)/height(cm)/BMI (kg/m2) at 16 weeks 
gestation. 
 
 
 
 
 
 
 86
  
 
87
APPENDIX B 
 
B. Association between Prenatal Serum Cotinine Concentrations and Weight, Height, and 
BMI Among Children with Complete Follow-Up 
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Table A2: Adjusted mean difference in weight, height, and BMI by change in mean prenatal serum cotinine concentrations among 
children with complete follow-up * 
 N (%)† Birth (N=194) 
4-Week 
(N=194) 
1 Year  
(N=192) 
2 Years  
(N=194) 
3 Years  
(N=194) 
Weight Models       
Categorical Prenatal Serum Cotinine Concentrations       
  Unexposed (<0.015 ng/mL) 83 (42.8) Ref Ref Ref Ref Ref 
  SHS (0.015-3 ng/mL) 95 (49.0) -58 (-236, 121) -68 (-252, 117) -5 (-384, 375) 242 (-269, 752) 376 (-264, 1015) 
  Active (>3 ng/mL) 16 (8.2) -18 (-367, 331) 48 (-310, 406) 515 (-182, 1211) 749 (-186, 1683) 1333 (171, 2496) 
Continuous Prenatal Serum Cotinine Concentrations       
  Log10-transformed mean cotinine 194 -49 (-144, 45) -40 (-136, 57) 29 (-145, 202) 80 (-148, 308) 223 (-58, 505) 
  Log10-transformed mean  
  cotinine  (Passively exposed women) ‡ 180 -82 (-251, 86) -100 (-273, 72) -181 (-495, 133) -95 (-502, 312) 0 (-487, 486) 
Height Models       
Categorical Prenatal Serum Cotinine Concentrations       
  Unexposed (<0.015 ng/mL) 83 (42.6) Ref Ref Ref Ref Ref 
  SHS (0.015-3 ng/mL) 96 (49.2) -0.5 (-1.3, 0.3) -0.4 (-1.1, 0.3) 0.1 (-0.8, 1.0) -0.1 (-1.1, 1.0) -0.1 (-1.3, 1.1) 
  Active (>3 ng/mL) 16 (8.2) -0.7 (-2.2, 0.8) -0.4 (-1.9, 1.0) 1.1 (-0.7, 2.9) 1.2 (-0.8, 3.2) 1.1 (-1.1, 3.4) 
Continuous Prenatal Serum Cotinine Concentrations       
  Log10-transformed mean cotinine 195 -0.3 (-0.7, 0.1) -0.2 (-0.6, 0.2) 0.1 (-0.3, 0.6) 0.1 (-0.4, 0.7) 0.1 (-0.5, 0.6) 
  Log10-transformed mean  
  cotinine  (Passively exposed women) ‡ 181 -0.4 (-1.1, 0.3) -0.4 (-1.1, 0.3) -0.1 (-0.9, 0.8) -0.1 (-1.1, 0.8) -0.4 (-1.4, 0.6) 
BMI Models       
Categorical Prenatal Serum Cotinine Concentrations       
  Unexposed (<0.015 ng/mL) 82 (42.4) Ref Ref Ref Ref Ref 
  SHS (0.015-3 ng/mL) 95 (49.2) 0.0 (-0.4, 0.4) 0.0 (-0.4, 0.4) 0.1 (-0.4, 0.5) 0.4 (-0.1, 0.9) 0.5 (0.1, 1.0) 
  Active (>3 ng/mL) 16 (8.3) 0.2 (-0.6, 1.0) 0.3 (-0.4, 1.0) 0.8 (-0.1, 1.6) 0.9 (0.0, 1.7) 1.4 (0.5, 2.2) 
Continuous Prenatal Serum Cotinine Concentrations       
  Log10-transformed mean cotinine 193 0.0 (-0.2, 0.2) 0.0 (-0.2, 0.2) 0.1 (-0.1, 0.3) 0.2 (-0.1, 0.4) 0.3 (0.1, 0.5) 
  Log10-transformed mean  
  cotinine  (Passively exposed women) ‡ 180 0.0 (-0.4, 0.4) 0.0 (-0.4, 0.3) -0.1 (-0.5, 0.3) 0.1 (-0.3, 0.5) 0.3 (-0.1, 0.7) 
*-Adjusted for maternal age (<25, 25-34, and >34 years), education (<12, 12, and >12 years), race (non-Hispanic white, non-Hispanic black, and 
other), marital status (married and non-married), depression at baseline home visit (moderately or severely depressed and mildly or minimally 
depressed), breast feeding duration since last visit (years), parity (0, 1, and >1), income ($10,000 increments), and maternal BMI (kg/m2) at 16 
weeks gestation. 
†-Sample size at birth 
‡-Women could not have serum cotinine concentration > 3 ng/mL at any measurement
 APPENDIX C 
 
 
C. Adjusted association between mean and individual serum cotinine concentrations and 
BMI at 2 and 3 years of age 
 
Table A3: Adjusted association between 16 week, 26 week, and birth serum cotinine 
concentrations and BMI at 2 or 3 years of age*  
 2 Year BMI 3 Year BMI 
 
Estimate  
(95% CI) CLD 
Estimate  
(95% CI) CLD 
Mean Serum     
LOD Ref  Ref  
Passive 0.3 (-0.1, 0.7) 0.8 0.4 (0.0, 0.8) 0.8 
Active 0.6 (-0.1, 1.4) 1.5 1.0 (0.3, 1.8) 1.5 
Continuous 0.2 (0.0, 0.4) 0.4 0.3 (0.1, 0.5) 0.4 
16 Week     
LOD Ref  Ref  
Passive 0.0 (-0.4, 0.5) 0.9 0.2 (-0.2, 0.6) 0.9 
Active 0.7 (-0.1, 1.5) 1.6 1.2 (0.4, 2.0) 1.6 
Continuous 0.0 (-0.1, 0.2) 0.4 0.2 (0.0, 0.4) 0.4 
26 Week     
LOD     
Passive 0.3 (-0.1, 0.7) 0.8 0.5 (0.1, 1.0) 0.8 
Active 0.8 (0.0, 1.5) 1.5 1.2 (0.4, 2.0) 1.5 
Continuous 0.2 (0.0, 0.3) 0.3 0.2 (0.1, 0.4) 0.3 
Birth     
LOD     
Passive 0.3 (-0.1, 0.8) 0.9 0.3 (-0.1, 0.7) 0.9 
Active 0.8 (0.0, 1.7) 1.7 1.1 (0.3, 1.9) 1.7 
Continuous 0.2 (0.0, 0.3) 0.4 0.3 (0.1, 0.4) 0.4 
*-Adjusted for child age (in years), child age squared, child age cubed, maternal age (<25, 25-
34, and >34 years), education (<12, 12, and >12 years), race (non-Hispanic white, non-Hispanic 
black, and other), marital status (married and non-married), depression at baseline home visit 
(moderately or severely depressed and mildly or minimally depressed), breast feeding duration 
since last visit (years), parity (0, 1, and >1), income ($10,000 increments), and maternal BMI 
(kg/m2) at 16 weeks gestation. 
†-Model with fit with birth, 4 week, and 1 year measurements.   
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